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Abstract
BIOBEHAVIORAL CORRELATES IN FIBROMYALGIA
By Ann Trivigno McNallen, CNM, MSN
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2012
Major Director: Nancy L. McCain, DSN, RN, Professor, VCU School of Nursing
Introduction: Fibromyalgia (FMS) is a chronic pain syndrome characterized by non-restorative
sleep, and fatigue. Over 75% of individuals with FMS complain of poor sleep quality and
fatigue. These have been ranked by patients with FMS as having great impact on quality of life.
A literature review suggested that poor sleep quality may be a predictor of increased stress and
FMS symptom onset in those affected. However, no experimental studies have demonstrated a
causal relationship between poor sleep and stress in people with FMS.
Methods: Using a single stage cross-sectional design, the primary study aim was to compare 25
women with FMS and 25 women without FMS, on the following variables: autonomic nervous
system activity; perceived stress; sleep quality; immune function (cytokines); and fatigue. The
secondary aim was to explore the relationships among the above variables within each group. A
third aim was to assess the validity of the Autonomic Symptoms Profile by comparing it to
measures of heart rate variability and selected sleep indices.
Significant Results: The FMS group had worse sleep quality, more autonomic symptoms, and
greater fatigue than the non-FMS group; they also had higher TNF-α levels. The non-FMS
group was more likely to have OSA. Non-FMS participants who had OSA also had higher IL-1β
values than the FMS group. Study variables that correlated with each other in the FMS group
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differed from those seen in the non-FMS group, with the exception of the positive correlation of
total arousals with AHI in both groups. In the FMS group, fatigue was positively correlated with
perceived stress, autonomic symptoms, and TNF-α; stress was positively correlated with
autonomic symptoms; and AHI was negatively correlated with IL-1β levels as well as the above
noted correlation with total arousals. In the non-FMS group, sleep quality was positively
correlated with fatigue, and sleep quality and fatigue were positively correlated with IL-1β. IL1β also positively correlated with TNF-α. Total arousals were negatively correlated with mean
RR interval. SDNN was correlated with RR interval and negatively correlated with AHI. The
hypothesis tests related to construct validity of the ASP indicated no significant supportive
correlations.
Keywords: fibromyalgia, stress, sleep quality, ANS dysfunction, fatigue, cytokines
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Chapter One

1

FIBROMYALGIA
Sleep quality is highly problematic for most people with fibromyalgia (FMS). It
appears to be related to autonomic nervous system (ANS) symptoms of dysfunction, such
as intestinal irritability, syncope, and excessive sensitivity to external stimuli, as well as
perceived stress, in people with FMS. Yet, no experimental studies thus far have
demonstrated a causal relationship between poor sleep and stress in people with FMS.
The biological mechanisms underlying such a relationship have not been fully articulated
either, although a genetic predisposition to ANS dysfunction has been posited. The
interplay of such a genetic predisposition, coupled with an adverse life event is viewed by
some investigators as a likely scenario for the new onset of chronic widespread pain
(CWP). Enhanced understanding of the biobehavioral mechanisms that result in FMS is
a priority research focus.
The two studies that comprise this dissertation seek to explore this area of interest.
In Chapter Two, an integrative literature review suggests that poor sleep quality may
precede the onset of CWP, which is the hallmark of FMS diagnosis. The 12 studies
included in the review agree that poor sleep quality is associated with greater perceived
stress and more pain in those with FMS, but because of their correlational designs a
causal link between poor sleep, stress, and pain cannot be posited. The directional nature
of these reported associations remains highly controversial. Chapter Three is the
Institutional Review Board application for permission to conduct an observational study,
which includes the study design in detail.
Chapter Four reports the results of that observational study; it compared two
groups of women presenting to the VCU Center for Sleep Medicine for evaluation of
poor sleep quality; one group with FMS, and one without such a diagnosis. These
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women were compared on measures of perceived stress, perceived sleep quality, fatigue,
and presence of ANS symptoms. They were assessed via polysomnography for objective
measures of sleep, and heart rate variability. Cytokine levels were also obtained and
compared.
Within the conceptual model of psychoneuroimmunology, this study initially
posited that biological and behavioral cofactors interact with the ANS in women with
FMS to produce dysfunctional changes in the ANS response to perceived stress, which in
turn might alter sleep quality and cytokine expression. Poor sleep quality also leads to
cytokine changes; both perceived stress and poor sleep quality interact with the ANS in a
circular fashion, which could result in generalized pain and fatigue.
The study findings revealed that the FMS group had significantly worse sleep
quality, more autonomic symptoms, and greater fatigue than the non-FMS group; they
also had higher tumor necrosis factor-alpha (TNF-α) cytokine levels. The non-FMS
group was significantly more likely to have obstructive sleep apnea (OSA). Non-FMS
participants who had OSA also had significantly higher Interleukin-1 beta (IL-1β)
cytokine values than those in the FMS group.
In the FMS group, fatigue was positively correlated with perceived stress,
autonomic symptoms, and TNF-α; stress was positively correlated with autonomic
symptoms; and apnea-hypopnea index (a measure of OSA presence and severity) was
negatively correlated with IL-1β levels.
In the non-FMS group, sleep quality was positively correlated with fatigue, and
sleep quality and fatigue were positively correlated with IL-1β. IL-1β also positively
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correlated with TNF-α. Study variables that significantly correlated with each other in
the FMS group differed completely from those seen in the non-FMS group.
These findings suggested a need to refine the postulated biobehavioral model of
FMS as a response to a dysfunction of the ANS. Specifically, it may be that genetic
predisposition, psychosocial experience, and behavioral cofactors interact in women with
FMS to produce ANS changes that alter response to perceived stress and increase
sympathetic nervous system (SNS) predominance during sleep. The SNS is viewed as
persistently hyperactive, yet paradoxically hypoactive to stressors such as nighttime
arousals, which may affect cytokine expression. Autonomic symptoms, including poor
sleep quality, and perceived stress may lead to additional cytokine changes, all of which
interact with the ANS in a circular fashion, resulting in generalized fatigue. This study
may shed light on the complex relationships of sleep quality, stress, and autonomic
symptoms in FMS in anticipation of formulating targeted interventions for sleep
symptom management.

4

FIBROMYALGIA

Chapter Two

5
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Fibromyalgia (FMS) is a chronic widespread pain syndrome characterized by diffuse
musculoskeletal pain, non-restorative sleep, fatigue, and psychological distress (Schaefer, 2003).
It affects approximately 5 million Americans (Lawrence et al., 2008), 90% of whom are women
(Bennett, Jones, Turk, Russell, & Matallana, 2007). The economic impact of this condition is
substantial as individuals with FMS often have trouble maintaining long-term employment due
to increasing disability (Birtane, Uzunca, Tastekin, & Tuna, 2007). Those who complain of
significant fatigue are six times more likely to report being disabled (Nicassio, Moxham,
Schuman, & Gevirtz, 2002). Mean annual healthcare expenditures per FMS patient were
reported to be more than $10,000 in a 2008 study (Silverman et al., 2009). Over 75% of FMS
patients internationally complain of poor sleep quality and fatigue (Belt, Kronholm, & Kauppi,
2009; Landis et al., 2003). These have been deemed critical in the management of FMS
(Nicassio et al., 2002; Ericsson & Mannerkorpi, 2007; Moldofsky, 2008). Current views of FMS
suggest it may be a neuroimmuno-endocrine inflammatory disorder exacerbated by stress
(Perrot, Dickenson, & Bennett, 2008).
Although FMS is considered a stress disorder, and highly implicated in poor sleep
quality, associations among stress and sleep quality in people with FMS have not been studied
extensively. The aim of this paper is to review the findings of studies about these particular
relationships. This integrative review seeks to answer the following question: what does current
research suggest about the relationships among stress, sleep and FMS symptomatology?
Background
Considered a state of threatened homeostasis (Martinez-Lavin, 2007), stress alters various
neuroimmuno-endocrine mechanisms (Kang, 2003). The stress response system, comprised
mainly of the autonomic nervous system (ANS) and the hypothalamic-pituitary-adrenal (HPA)
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axis, operates dynamically to maintain homeostasis. The ANS is the interface between one’s
perceptions and physiology that triggers a person’s responses to a particular situation. Potential
ANS responses to stress include elevated blood pressure, heart, and respiratory rates, pupil
dilation, vasoconstriction, and shunting of circulation from the intestines to the skeletal muscles.
Perceived stress is defined as a person’s cognitive appraisal of insufficient coping
resources (Lazarus & Folkman, 1984), and is thought to increase sympathetic nervous system
(SNS) activity (Martinez-Lavin, 2007). Studies of individuals with FMS have detected stress
intolerance (Sephton et al., 2007) and increased basal SNS tone (Lush et al., 2009). FMS
patients’ reports that their pain is intensified by stress have been corroborated by researchers
(Bradley, 2008). In a cross-sectional survey of 201 individuals, level of perceived stress was
found to account for the greatest amount of variance associated with FMS symptoms (Murray,
Murray, & Daniels, 2007).
The degree to which pain is experienced as a stressor may be exacerbated in people with
FMS as compared to other people with chronic pain. Zautra et al.(2005) found that people with
FMS displayed heightened stress responses as compared to people with osteoarthritis (OA) who
reported similar pain levels. They found that stress-related increases in pain were more
exacerbated by negative mood in individuals with FMS patients than in people with OA (Zautra
et al., 2005). Additionally, general coping styles of people with FMS may differ from those of
healthy controls (Ablin, Cohen, Neumann, Kaplan, & Buskila, 2008); this alteration in coping
ability has been thought to leave those with FMS more vulnerable to stress than individuals with
similar chronic pain conditions (Davis, Zautra, & Reich, 2001; Weissbecker, Floyd, Dedert,
Salmon, & Sephton, 2006).
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Nearly 100% of people with FMS have reported poor sleep quality (Rizzi et al., 2004).
Individuals with FMS scored significantly worse than healthy controls on instruments measuring
sleep quality in two studies; they reported sleeping an average of only four to six hours per night
(Osorio, Gallinaro, Lorenzi-Filho, & Lage, 2006; Bigatti, Hernandez, Cronan, & Rand, 2008).
Osorio et al. (2006) found that Pittsburgh Sleep Quality Index (PSQI) scores were three times
higher in participants with FMS than healthy controls on all questionnaire components except
use of sleep medications. Sleep problems most commonly reported by those with FMS include
difficulty falling asleep, nighttime arousals and fatigue on arising (Shah, Feinberg, & Krishnan,
2006; Bigatti et al., 2008; Osorio et al., 2006).
This self-report data has been supported by studies that explored sleep quality in FMS
using polysomnography (PSG) (Shah et al., 2006) and actigraphy (Landis et al., 2003). Those
with FMS have been found to be more easily aroused from sleep (Shah et al., 2006; Rizzi et al.,
2004) and have higher levels of physical activity at night than control participants (Shah et al.,
2006; Korszun et al., 2002; Landis et al., 2003). PSG has indicated that people with FMS have
interrupted deep sleep, i.e. repeated arousals due to insertion of rapid-eye-movement (REM)
sleep, also known as alpha wave intrusions or alpha-delta sleep (Peterson, 2007; Shah et al.,
2006). Abad et al.(2008) found that individuals with FMS had significantly shorter stage 2 sleep
durations than healthy controls and that shorter overall sleep duration was predictive of increased
pain in those with FMS. Landis et al. (2004) reported that stage 1 non-rapid-eye-movement
(NREM) sleep was significantly increased and sleep spindle activity in stage 2 sleep was
significantly decreased in participants with FMS as compared to healthy controls. These
findings positively correlated with pain levels in those with FMS. Rizzi et al.(2004) found that
study participants with FMS had a 29% increase in the rate of cyclic alternating patterns
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compared to healthy controls and noted that this disturbance in sleep microstructure dynamics
highly correlated with reports of poor sleep quality in those with FMS. Other PSG findings that
have been reported in FMS include decreased total sleep time, decreased delta sleep, and
decreased REM sleep percentages (Harding & Hawkins, 2005).
Poor sleep has been associated with greater pain (Bigatti et al., 2008; Agargun et al.,
1999) and fatigue (Landis et al., 2003; Hamilton et al., 2008) in those with FMS. In a
longitudinal study of 492 people with FMS, sleep disturbance was found to have a predictive
relationship to pain (Bigatti et al., 2008). Conversely, improving sleep quality has been reported
to decrease levels of pain and fatigue in people with FMS and has been viewed as a barometer
for clinical symptom management (Perrot et al., 2008; Peterson, 2007). Women with FMS have
been reported to have 19 to 25% rates of sleep apnea/hypopnea (Shaver, 2008). In comparison,
the rate of sleep apnea hypopnea syndrome has been reported to be 2% in women less than age
65 in one cohort study of state employees (Young, Peppard, & Gottlieb, 2002). Yet
identification and treatment of comorbid sleep disorders in people with FMS, such as obstructive
sleep apnea, has not consistently led to improvement in FMS symptoms (Dadabhoy, Crofford,
Spaeth, Russell, & Clauw, 2008).
Methods
A literature search was conducted in summer 2009 and updated April 2011 for the years
ranging from 1990 to 2011. Databases searched included: the Cochrane Library; Medline; Web
of Science; ISI Web of Knowledge; PsychInfo; and CINAHL. Search terms used were: stress;
perceived stress; psychological stress; psychological distress; sleep; sleep quality; insomnia; and
fibromyalgia. Positive and negative affect were included terms if they were related in the study
to stress or distress. Criteria for inclusion were that the citations be quantitative research studies
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that examined stress and sleep quality in study participants with FMS. One citation was found
that included three variables (stress, sleep quality, and FMS). As a result of this small return,
citations were then examined that included at least two of these factors. Also perused were
studies that cited the first retrieved article and included either stress and FMS or sleep and FMS.
Their listed references were also searched for any studies that might meet inclusion criteria. A
total of 142 citations were retrieved; 57 were excluded because they contained only two of the
three variables of interest; 23 were excluded as medication studies, 2 were excluded as not
available in English, 42 were excluded because they did not contain any of the variables of
interest, and 3 were excluded as survey articles. Finally, 12 studies were found that contained all
three variables (stress, sleep quality, and FMS). This search strategy is depicted in Figure 1.
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Figure 1
Literature Search Methods
Databases
CINAHL; Cochrane Library; PsychInfo; Medline;
Web of Science; ISI Web of Knowledge

Search 1: Stress,
Sleep, and FMS (1)

Search 2: Studies with sleep/FMS or
stress/FMS and references that cited
the study in Search 1 (182)

Total retrieved (138)

Included:
Contained all 3
variables (12)

Excluded:
(122)

Final review:
(12)

11

Search 3: References
listed in studies in
Search 2 (15)
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Table 1
Studies Reviewed
Study
Uveges et al.
(1990)

Purpose
Compare psychological profiles of people
with FMS and RA, based on pain, health
status, stress, and sleep quality.
Shaver et al.
Compare sleep quality, psychological
(1997)
distress, PSG data and stress arousal in
women with and without FMS.
Landis et al.
Compare pain, depression, psychological
(2004)
distress, mood, sleep, and immune
biomarkers in women with and without
FMS.
Hamilton Catley Assess the role of sleep duration and
& Karlson
quality in stress responses of women with
(2007)
FMS.
Gupta et al.
Can new onset CWP be predicted by
(2007)
psychological distress, health seeking
behavior, poor sleep, or traumatic events?
McBeth et al.
Do HPA stress response abnormalities
(2007)
moderate between HPA function and new
onset of CWP?
TheadomCropley Explore the effect of sleep and coping on
& Humphrey
health-related QoL* in people with FMS.
(2007)
Hamilton et al.
Assess the role of sleep in affect, stress
(2008)
reactivity, and recovery from stress in
people with FMS.
Theadom &
Compare sleep-related dysfunctional
Cropley (2008)
beliefs, stress and sleep quality of people
with FMS with controls.
Davies et al.
Does good quality sleep predict resolution
(2008)
of CWP?
White, Faull &
Explore stress and sleep quality in a
Jones (2009)
phone survey sample of people with FMS
10 years after a rehab intervention and
compare results with earlier intake data.
Riva et al. (2010) Examine free salivary cortisol levels and
sleep quality in people with FMS as
compared to controls.
*CWP= chronic widespread pain

*QoL= quality of life

12

Design
Cross-sectional

Sample
N=47

Retrospective
cohort

N=22

Prospective cohort N=70

Prospective

N=49

Prospective cohort N=3185

Prospective cohort N=241

Cross-sectional

N=101

Prospective

N=89

Prospective cohort N=166

Prospective cohort N=679
Prospective cohort N=29

Cross-sectional

N=58
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Results
These 12 studies point to a circular relationship between sleep quality and stress in
individuals with FMS. They all agree that poor sleep quality is associated with greater perceived
stress and more pain in those with FMS, but because of their correlational designs a causal link
between the two was not posited. The direction of this relationship remains in question. Does
greater stress predict poor sleep quality or vice versa? Is the relationship bidirectional? Might it
differ from person to person, or even within a person at different times? The following studies
shed some light over time on this issue, but it is far from resolved.
PSG Changes
Landis et al. (2004) compared pain, psychological factors, subjective and objective sleep
quality, lymphocyte phenotypes and activation markers, and natural killer cell activity in women
with and without FMS. Psychological factors studied included depression, psychological
distress, mood state, anxiety, post-traumatic stress syndrome (PTSD), bipolar disorder, and
alcohol or drug abuse. Pain was assessed by tender point and pressure pain threshold elicitation.
Sleep was evaluated by PSG and participant reports. Participants with FMS reported more
depression, more psychological distress, less vigor, lower pain threshold, and rated sleep quality
worse than the control group. PSG data demonstrated that only the group difference in NREM
stage 2 sleep was statistically significant, however. The authors noted that the participants with
FMS reported poor sleep quality out of proportion to the modest differences seen on PSG as
compared to controls.
Shaver et al. (1997) compared sleep quality, psychological distress, PSG data, and
physiological stress in women with and without FMS. Physiological stress was determined by
heart rate, muscle tension, temperature, and skin conductance. Urinary catecholamines and
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cortisol were assayed. Participants with FMS reported significantly worse sleep than the controls
and also scored significantly higher on anxiety, somatization, and obsessive-compulsive
subscales. PSG data indicated that participants with FMS had significantly more stage 1 sleep,
more sleep stage changes, and more sleep fragmentation than controls, but only during the first
half of the night. No significant differences in PSG data were seen between the two groups for
the entire night. Physiological stress did not differ significantly between the two groups.
Riva et al. (2010) assessed pain, perceived stress, salivary cortisol levels, heart rate
variability, and PSG measures of sleep quality in women with and without FMS. They reported
that women with FMS had lower cortisol levels than controls, as well as less total sleep time, and
poorer sleep efficiency. No correlation was found between PSG data and cortisol levels in either
group.
Sleep and CWP
Davies et al. (2008) explored the hypotheses that good sleep quality would predict the
resolution of symptoms of chronic widespread pain (CWP) within 15 months, and that these
relationships would be independent of any confounding psychological factors. CWP was
defined based on the American College of Rheumatology (ACR) criteria for FMS[VSM1] (Wolfe et
al., 2010). A follow-up questionnaire 15 months later assessed pain status. Of the four
components of sleep quality, (sleep onset; sleep maintenance; early wakening; restorative sleep)
after controlling for psychosocial factors, only restorative sleep was associated with CWP
resolution. The authors concluded that restorative sleep was independently associated with the
resolution of CWP in their study respondents.
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Sleep, Stress, and CWP
Hamilton et al. (2008) hypothesized that sleep disturbance is a predictor of daily affect,
reaction to stressors, and recovery from stress in women with FMS. They used participants’
recordings of their positive and negative affective states, the occurrence of positive and negative
events, and their sleep quality. Duration and quality of sleep predicted the type of affective state
and ease of cognitive functioning in their participants. Poor sleep quality seemed to inhibit the
restoration of a participant’s positive affect following a day with a high number of negative
events, whereas type of daily events and affect did not predict future sleep quality. They
concluded that sleep duration and quality seem to play central roles in daily functioning for
people with FMS, predicting subsequent daily mood, ease of cognitive functioning, and degree
of pain. They speculated that sleep disturbance may lie upstream of central processing
anomalies that have been theorized to drive the onset of FMS.
Hamilton, Catley and Karlson (2007) then examined sleep duration and quality as a
correlate of stress reactivity and pain in people with either rheumatoid arthritis (RA) or FMS.
They hypothesized that quality and duration of sleep would moderate affective responses to
stress and pain. They found that participants with FMS reported more pain and worse sleep
quality than the participants with RA, yet sleep duration and averaged positive and negative
affect did not differ between the groups. They concluded that sleep disturbance appeared to
interfere with participants’ adjustments to stress and pain, whereas good quality restorative sleep
moderated response to stress and pain. The researchers noted that pain seemed to be the most
important determinant of subjective sleep quality, yet sleep deprivation also alters a person’s
pain threshold. They were unable to determine whether improved sleep quality is a mechanism
for, or a marker of, improvement.
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Gupta et al. (2007) explored the relative contributions of psychological distress, healthseeking behavior, sleep problems, and traumatic life events to the development of new onset of
CWP. CWP was defined using the ACR criteria for FMS. Three factors independently
contributed to the odds of participants’ experiencing new onset CWP, in a dose-response fashion:
illness behavior, somatic symptoms, and sleep disturbance. Reports of multiple physical
symptoms, help-seeking for health problems, sleep disturbance, and the occurrence of an adverse
life event increased the likelihood of a participant having new onset CWP in the next 15 months
20-fold. The presence of at least one of the above factors predicted 93% of new cases of CWP.
Their conclusion was that sleep disturbance and adverse life events often preceded the onset of
CWP within 15 months.
Stress, Sleep, and CWP
Uveges et al. (1990) compared participants with FMS and RA on measures of
psychological distress, pain, health status, stress, sleep disturbance and coping. The FMS group
reported significantly more psychological distress, more pain, more life stress, more sleep
disturbance, and more impaired health status than the RA group. The groups did not differ in
their use of coping strategies. The FMS group did not have more physical disability than the RA
group. Participants with FMS reported more psychological distress and a greater occurrence of
sleep disturbance than participants with RA with comparable pain levels. The researchers
concluded that the high levels of life stress reported by people with FMS may have affected their
overall psychological responses.
Theadom, Cropley, and Humphrey (2007) explored the effect of sleep and coping on
health-related QoL in people with FMS using mailed questionnaires. They examined sleep
quality, coping, positive and negative affect, physical functioning, social functioning, pain,
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fatigue, emotional wellbeing, and general health. Poor sleep was reported by 99% of the
participants. The occurrence of negative affect reported by participants was significantly
correlated with their reports of poor sleep quality and lower use of coping strategies. No
association was detected between sleep quality and particular coping strategies.
Theadom and Cropley (2008) then sought to compare sleep-related dysfunctional beliefs,
stress levels and sleep quality of participants with and without FMS. They used questionnaires
of dysfunctional beliefs and attitudes about sleep, perceived stress, fatigue, pain, and sleep
quality. They found that, compared to controls, participants with FMS reported significantly
higher levels of perceived stress, dysfunctional beliefs about sleep, pain, fatigue, and poorer
sleep quality. The dysfunctional beliefs and attitudes about sleep of the participants with FMS
were significantly associated with their pain, fatigue, and poorer sleep quality. More perceived
stress was associated with higher levels of fatigue, pain, more sleep disturbance, and greater
daytime dysfunction in the participants with FMS. The most common sleep disturbances
reported were increased sleep latency insomnia and sleep maintenance insomnia.
McBeth et al. (2007) hypothesized that HPA-axis stress response abnormalities would
moderate the effect of HPA functions and new onset of CWP, independently of psychosocial
factors. Participants without CWP but at risk of developing it, based on their psychosocial
profile, had their HPA axis function assessed and were followed over 15 months. CWP was
defined using the ACR criteria for FMS. Psychosocial factors studied included psychological
distress; health anxiety; illness behavior; depression; anxiety; and sleep disturbance. HPA axis
function was determined by serum cortisol levels in response to a pain threshold examination and
a low-dose dexamethasone suppression test, as well as salivary cortisol levels obtained in the
morning and evening to assess diurnal HPA axis function. At follow-up, new-onset CWP was
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identified by the same criteria. Any occurrence of stressful life events was elicited. 11.6% of the
participants developed CWP. High levels of cortisol post-dexamethasone, low morning salivary
cortisol, and high evening salivary cortisol were all significantly associated with CWP onset.
One or more of these three factors identified 93% of the new onset CWP cases; their effects were
independent of each other, but additive as predictors of CWP. Higher levels of sleep
disturbance, having experienced two or more high-stress events, and higher illness behavior were
associated with some, but not a significantly increased, risk of CWP. They concluded that HPA
axis dysfunction predicted an increased risk of the new onset of CWP.
White et al. (2009) conducted a telephone survey of 29 respondents with FMS who had
participated in an intensive rehabilitation program 10 years earlier, and compared their reports
from the initial interviews to the present ones. They found that in the intervening years stress
levels had declined but that sleep quality had not changed. Yet, they also found that lower
reported stress levels did covary with improved sleep quality.
Discussion
Uveges et al. (1990), Landis et al. ( 2004), White et al.( 2009), and Shaver et al.(1997) all
confirmed the association between stress and sleep quality in women with FMS but made no
directional claims. Hamilton and Catley (2007) reported that sleep disruption interferes with a
positive adjustment to stress, whereas restorative sleep moderates the response to stress in people
with FMS. In a follow-up study they concluded that poor sleep quality prevented the restoration
of positive affect following a day with a high number of negative events, whereas daily events
and affect did not predict future sleep quality (Hamilton et al., 2008). They opted for poor sleep
quality being a predictor of increased stress in FMS patients. Theadom and Cropley (2008) and
Theadom, Cropley and Humphrey (2007) confirmed the association between stress and poor
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sleep quality; they noted that both factors contributed to predictions of pain and fatigue. Davies
et al. (2008) reported that restorative sleep was associated with resolution of symptoms of CWP,
but found no relationship between psychological distress and sleep quality. Gupta et al. (2007)
reported that both sleep and stress are implicated in the onset of new CWP. McBeth et al. (2007)
also found that recent stressful life experiences predicted new CWP onset.
The evidence thus far suggests that poor sleep quality may be a predictor of increased
stress and FMS symptom onset in those affected. However, no experimental studies have
demonstrated a causal relationship between poor sleep and stress in people with FMS. One
reason for this uncertainty is that the biological mechanisms underlying such a relationship have
not been fully articulated, although a genetic predisposition to ANS dysfunction has been posited
by investigators. The interplay of such a genetic predisposition, coupled with an adverse life
event seems a likely scenario for the new onset of CWP. Enhanced understanding of the core
biological mechanisms that result in FMS is a priority research focus. The search for useful
biomarkers of both stress level and sleep quality in people with FMS is a fertile area for basic
research endeavors as well. Of these 12 studies, the authors of seven indicated that further
research into the nature of sleep quality and interventions designed to improve it are needed for
the development of FMS symptom management approaches. Further investigation into the role
of sleep quality in relation to the predisposition to, or treatment of FMS is warranted as well.
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VCU RESEARCH PLAN TEMPLATE
Use of this template is required to provide your VCU Research Plan to the IRB. Your responses should be written in terms
for the non-scientist to understand. If a detailed research protocol (e.g., sponsor’s protocol) exists, you may reference that
protocol. NOTE: If that protocol does not address all of the issues outlined in each Section Heading, you must address
the remaining issues in this Plan. It is NOT acceptable to reference a research funding proposal.
ALL Sections of the Human Subjects Instructions must be completed with the exception of the Section entitled
“Special Consent Provisions.” Complete that Section if applicable. When other Sections are not applicable, list the Section
Heading and indicate “N/A.”
NOTE: The Research Plan is required with ALL submissions and MUST follow the template, and include version
number or date, and page numbers.

DO NOT DELETE SECTION HEADINGS OR THE INSTRUCTIONS.
I. TITLE
A BIOBEHAVORAL MODEL OF FIBROMYALGIA

II. STAFFING
A. In the table below (add additional rows as needed), indicate: (1) key project personnel including the principal
investigator and individuals from other institutions, (2) their qualifications, and (3) a brief description of their
responsibilities.
NAME OF INDIVIDUAL
Nancy L. McCain
Ann T. McNallen

QUALIFICATIONS
RN, DSN, FAAN
RN, CNM, MSN, PhD Candidate

RESPONSIBILITIES
Principal investigator (PI).
Student investigator will serve as the
primary contact for the study and be
responsible for all data collection.

B. Describe the process that you will use to ensure that all persons assisting with the research are adequately
informed about the protocol and their research-related duties and functions.
The PI will provide training to the student investigator as a function of the dissertation process. In addition, the student
investigator will conduct a trial run of the study prior to enrolling any participants. No other personnel are involved in this
research.
III. CONFLICT OF INTEREST
Describe how the principal investigator and sub/co-investigators might benefit from the subject’s participation in this
project or completion of the project in general. Do not describe (1) academic recognition such as publications or (2)
grant or contract based support of VCU salary commensurate with the professional effort required for the conduct of
the project
The researchers will not financially benefit from subjects’ participation or completion of this project. There are no
conflicts of interest to report.
IV. RESOURCES
Briefly describe the resources committed to this project including: (1) time available to conduct and complete the
research, (2) facilities where you will conduct the research, (3 availability of medical or psychological resources that
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participants might require as a consequence of the research (if applicable), and (4) financial support.

The student investigator will be conducting this research full time in fulfillment of her dissertation requirements. The
Virginia Commonwealth University (VCU) Center for Sleep Medicine is the primary data collection site, and this study
has received the full support of Dr. David Leszczyszyn, MD, PhD, the medical director of this facility. The student
investigator has the resources of an appointed doctoral committee for advice and consultation on data collection, entry,
data analysis, and preparation of results. The Center for Biobehavioral Clinical Research (CBCR) lab of the VCU School
of Nursing is the site for the storage and analysis of blood samples. Lab data will be processed there using resources
available to the PI.
V. HYPOTHESIS
Briefly state the problem, background, importance of the research, and goals of the proposed project.
Fibromyalgia (FMS) is a chronic pain syndrome characterized by diffuse musculoskeletal pain, non-restorative
sleep, fatigue, and psychological distress1. It affects approximately 5 million Americans2, 90% of whom are women3.
Most people are diagnosed in middle age4, and incidence increases with age; by age 80 nearly 8% of adults may be so
classified 5. The economic impact of this condition is substantial; individuals with FMS often have trouble maintaining
long-term employment due to increasing disability6. It has been estimated that 10% of FMS patients are disabled, 30% are
forced to change employment, and another 30% modify their jobs to remain employed7. Those who complain of significant
fatigue are 6 times more likely to report being disabled 8. Close to $20 billion is spent annually in the US on diagnosis and
treatment of FMS7. Mean annual healthcare expenditures per FMS patient have been reported to be more than $10,0009.
Over 75% of FMS patients internationally complain of two components of this disability, poor sleep quality and fatigue
10;11
. These factors have been deemed critical in the treatment of FMS8;12;13. Pain, disordered sleep, and fatigue have been
ranked by FMS patients as symptoms having great impact on their quality of life14;15. Current views of FMS suggest it may
be a neuroimmunoendocrine inflammatory disorder exacerbated by stress16; although multiple hypotheses have been
advanced for its etiology, there is no current consensus.
The relationships among autonomic nervous system (ANS) function, perceived stress, sleep quality (as measured
by polysomnography [PSG] and patient self-report), fatigue, pain, and immune function (as measured by plasma cytokine
levels) have not been explored together in a study of participants referred to a Sleep Center. Stress and its relationship to
sleep in FMS has been studied17, and cytokine expression in FMS has been also been examined18. The relationships
among ANS dysfunction, stress, sleep, and cytokines in FMS are undergoing increased scrutiny, but whether these
variables correlate with pain and fatigue in FMS patients remains unexplored19.
Study Hypotheses
To study Aim 1, it is being hypothesized that the FMS group, in comparison to the non-FMS group, will
demonstrate significantly: higher Composite Autonomic Symptom Scale (COMPASS) scores; lower heart rate variability
(HRV); higher Perceived Stress Scores (PSS); higher Pittsburgh Sleep Quality Index (PSQI) scores; greater sleep
disturbance as evidenced by an increased number of sleep arousals on PSG; an increased ratio of pro- to anti-inflammatory
cytokines; and greater Brief Fatigue Inventory (BFI) scores.
For Aim 2, correlations among ANS activity (COMPASS and HRV), perceived stress (PSS), sleep quality (PSG
and PSQI), immune function (17-plex cytokines), and fatigue (BFI) will be explored within each group. Also, within the
FMS group, these variables will be correlated with pain, using the Brief Pain Inventory (BPI). It is being hypothesized that
different correlation patterns will be observed in the FMS group than the non-FMS group.
To study Aim 3, it is being hypothesized that construct validity of the COMPASS will be demonstrated by
meaningful correlations between COMPASS scores and HRV, as well as selected PSG sleep indices (number of arousals
and sleep latency).

VI. SPECIFIC AIMS
Aim 1 of this proposal is to compare two groups, 25 women with and 25 women without FMS, on the following
variables: ANS activity; perceived stress; sleep quality; immune function (17-plex cytokines; and fatigue.
Aim 2 is to explore the relationships among the above variables within each group of participants. Within the FMS
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group, these variables will also be correlated with pain.
Aim 3 is to assess the validity of the COMPASS by comparing it to measures of HRV and sleep indices (number
of arousals and sleep latency). The clinical relevance of ANS function and the study of stress in FMS patients lies in the
evidence that ANS stress responses are altered in FMS as compared to healthy individuals experiencing stress20, but the
underlying mechanisms are not well understood.

VII. BACKGROUND AND SIGNIFICANCE
Include information regarding pre-clinical and early human studies. Attach appropriate citations.
Psychoneuroimmunology (PNI) is the research framework being used to guide this proposed study. PNI is the term
used to identify an interdisciplinary field of research related to investigating mind-body relationships, i.e., interactions of
behaviors, brain function, the neuroendocrine and neuroimmune systems. The field of PNI was developed further within a
biobehavioral framework by Dr. Nancy McCain and others in the VCU School of Nursing’s Center for Biobehavioral
Clinical Research (CBCR) (P20 NR008988, 2004-2009).
A basic goal of this biobehavioral research is translation of neuroimmune mechanisms into an understanding of
clinically relevant mechanisms and outcomes21. PNI has been employed as a biobehavioral nursing model by researchers
to explore interactions among psychosocial, behavioral, environmental, and biological variables in a holistic fashion22.
Nursing research has used PNI as a framework to examine relationships among biological and behavioral correlates and
their effects on patient outcomes23. In particular, PNI has been used as a framework for exploring stress and coping
mechanisms as they relate to health outcomes in various cohorts of chronically ill patients24. The model for the proposed
study (Figure 1) posits that particular biological and behavioral cofactors interact with the ANS in women with FMS to
produce dysfunctional changes in the ANS response to perceived stress, which in turn alter sleep quality and cytokine
expression. Poor sleep quality leads to cytokine changes; both interact with the ANS in a circular fashion, resulting in
generalized pain and severe fatigue. Pain further diminishes sleep quality, leading to a vicious cycle of non-restorative
sleep, fatigue, stress, and pain.
The extent to which expression of FMS symptoms accounts for cytokine changes independent of sleep quality is
unclear. It is also unknown which particular aspects of sleep in FMS, such as length of sleep stages or number of arousals,
may be predictive of cytokine changes and pain or resultant from them. Additionally, perceived stress has been implicated
in worsening sleep quality, pain, and fatigue for FMS patients, but the degree to which it initiates or reflects ANS stress
arousal remains unclear. This study seeks to shed light on these complex relationships in anticipation of formulating
targeted clinical interventions for symptom management.
Figure 1: PNI-based Biobehavioral Model of Symptoms in FMS
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ANS factors
Several lines of evidence support a physiologic basis for FMS. While etiology is unclear, disordered pain
processing through central sensitization seems to play a role in symptom development16;25;26. N-methyl-D-aspartate
receptors may become activated, leading to central sensitization of nocioceptive neurons in the dorsal horn of the spinal
cord27. FMS is thought by some investigators to result from ANS dysfunction, initiated by a genetically impaired stress
response20;28. Another example of ANS dysfunction being linked to FMS is provided by the prevalence of postural
orthostatic tachycardia syndrome (POTS), in FMS patients. This common event experienced by FMS patients during tilt
table testing is defined as a heart rate increase of more than 30 beats per minute after more than 3 minutes of standing
upright29.
First-degree relatives of FMS patients have an 8-fold increased risk of developing FMS in comparison to the
general population30 and display enhanced pain sensitivity to multiple stimuli31. A polymorphism of the catecholamine omethyl transferase gene may predispose individuals under stress to have a hyperactive sympathetic nervous system (SNS)
response, resulting in poor sleep and anxiety30;32.
ANS dysregulation of pain modulatory systems may lead to prolonged interactions among the central nervous
system (CNS), the peripheral nervous system, and the immune system, such that the characteristic of neuroplasticity
enables a connection to be made among the SNS and nocioceptive fibers. This is postulated to result in neuropathic pain25.
Implicated in this putative neuroplastic response is a stress response that induces sodium channels to up-regulate and
initiate sympathetic sprouting in the dorsal root ganglia of the spinal cord through nerve growth factor overexpression33.
FMS has been associated with low serotonin levels and elevated Substance-P levels32; it has been hypothesized that the
combination of the 2 results in heightened pain perception34.
Multiple sensory perceptions, including pressure and heat, may be altered for FMS patients; it has been reported
that 20 FMS patients exhibited decreased noise tolerance compared to either 20 osteoarthritis patients or 20 controls35.
Other investigators found that 16 FMS patients displayed greater awareness of unpleasant odors and less awareness of
pleasant ones than 15 matched controls36. A neuroimaging study provided corroboration of those findings, evidenced by
heightened activity in specific brain regions in response to pressure and heat in 9 FMS patients as compared to 9 controls37.
These instances of enhanced perception of unpleasant stimuli have been posited to be further evidence of CNS alteration,
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heightened response to sensory input, and a perceptual style of amplification, which has been termed generalized
hypervigilance35. Light et al.25 reported that 54 FMS patients displayed altered adrenergic function as compared to 34
controls; they view the SNS as persistently hyperactive, yet paradoxically hypoactive to acute stressors due to receptor
desensitization20. They hypothesized that the stressed SNS is overwhelmed, and due to a ceiling effect, unable to respond
to further stress; this, they speculated, might be related to the fatigue of FMS.
Stress and the ANS
Considered a state of threatened homeostasis20, stress alters various immune mechanisms including lymphocyte
production, natural killer cell activity, cytokine and antibody production, phagocytosis and oxidative stress22. The stress
response system, comprised mainly of the ANS and the hypothalamic-pituitary adrenal (HPA) axis, operates dynamically
to maintain this homeostasis. The ANS regulates essential involuntary functions such as vital signs and is activated by
centers in the brain stem, the spinal cord, hypothalamus, and thalamus. It is the interface between the mind and body that
alerts an organism to respond to a particular stressor. ANS effects include elevated blood pressure (BP), pulse and
respiratory rate; pupil dilation; vasoconstriction; and shunting of circulation from intestines to skeletal muscles. Nilsen et
al.38 found lower diastolic BP and increased pain in response to stress in 23 FMS patients as compared to 35 controls.
Normal beat-to-beat HRV is the signature of a healthy ANS response to perceived changes in the environment,
and appears to be a reliable biomarker of stress39. FMS patients have been reported to display less HRV compared to
controls30;38. ANS hyporeactivity seems to be correlated with fatigue, low BP, dizziness, and faintness in FMS patients as
well39. It has been reported that women with FMS respond with altered cardiovascular dynamics to resistance exercise40,
and that resistance training can improve HRV in FMS patients41. However, in a recent meta-analysis of HRV and
functional somatic disorders studies, including FMS, Tak et al. concluded that current evidence is insufficient to confirm
this claim42. Sleep is also affected by the ANS; HRV changes are reported to precede arousals from deep sleep and the
onset of REM sleep by up to 20 beats per minute39. Therefore general ANS response patterns in FMS, as well as HRV
specifically, are areas requiring continued investigation.
Perceived stress
Perceived stress is a person’s cognitive appraisal of insufficient coping resources43 and has been thought to
increase SNS activity20. FMS studies have detected stress intolerance or outright psychological distress44 and increased
basal SNS tone45. Theadom & Cropley17 found that 83 FMS patients had significantly higher levels of perceived stress as
compared to 83 controls. Their patients reported that pain was intensified by stress and this has been corroborated by other
studies31. Level of perceived stress was found to account for the greatest amount of variance associated with FMS
symptoms in a cross sectional survey of 201 individuals with FMS46.
Stress perception is potentially unbounded by time; up to 64% of FMS patients report a history of childhood
trauma, which was correlated to elevated evening cortisol levels in 85 FMS patients47. Childhood abuse may be a chronic
emotional stressor that dysregulates FMS patients’ endocrine function into adulthood48. Factors associated with the onset
of FMS are infection (55%), physical trauma (14-23%), and emotional trauma or acute stress (14%); up to 65% of FMS
patients report a history of sexual abuse27. Cohen et al.49 found that 57% of 77 FMS patients reported clinically significant
post-traumatic stress disorder (PTSD) symptoms, including avoidance, hyperarousal, and re-experiencing events, as well
as anxiety and depression.
The degree to which pain is experienced as a stressor may be heightened in FMS. Zautra et al.50 found that 87
FMS patients displayed heightened stress responses to pain as compared to 39 patients with osteoarthritis. Positive affect
as a coping mechanism for stress was diminished in patients with FMS as compared to those with osteoarthritis; stressrelated increases in perceived pain were exacerbated by negative mood in the FMS group50. Ablin et al.48 reported that
general coping styles of 77 FMS patients with or without PTSD varied from those of 48 controls. This may be associated
with FMS patients being more vulnerable to stress than individuals with other chronic pain conditions47;51. Perceived stress
has been independently associated with poor sleep quality and increased nighttime arousals; ruminating about pain at
bedtime predicted longer sleep onset latency and total duration of night arousals in 83 FMS patients as compared to 83
controls17.
Sleep quality and FMS
ANS activity drives many physiologic changes that occur during sleep52. Nearly 100% of FMS patients report
poor sleep quality4;17;53. FMS patients have scored significantly worse than controls on instruments measuring sleep
quality in several studies17;54;55; Osorio et al.54 found that Pittsburgh Sleep Quality Index (PSQI) scores were 3 times higher
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in 30 FMS patients than 30 controls on all questionnaire components except sleep medications. FMS patients have
reported sleeping an average of 4 to 6 hours per night and waking up unrefreshed17;34;54;55. Sleep disturbances commonly
reported have included difficulty falling asleep, nighttime arousals and fatigue upon arising17;54-56.
These findings have been supported by PSG56 and actigraphy11, which suggest that FMS patients are more easily
aroused from sleep4;4;17;56 and have higher levels of physical activity at night than controls11;17;56;57. PSG studies have
indicated that FMS patients have interrupted deep sleep, i.e., repeated arousals, due to insertion of rapid-eye-movement
(REM) sleep, known as alpha wave intrusions or alpha-delta sleep34;56. Other investigators noted that alpha intrusion
during sleep can be of different patterns; phasic alpha sleep activity was the pattern they found better correlated with FMS
symptoms58. Abad et al.59 found that 15 FMS patients displayed significantly shorter durations of stage 2 sleep than 15
controls, which was predictive of pain reports. Landis et al.11 reported increased stage 1 non-rapid-eye-movement (NREM)
sleep; sleep spindles in stage 2 sleep of 37 FMS patients were significantly decreased compared to 30 controls, which also
correlated with increased sub-sequent pain. Rizzi et al.4 found that 45 FMS patients (vs. 38 controls) had a 29% increase
in the rate of cyclic alternating patterns; this disturbance in sleep microstructure dynamics was closely correlated to FMS
patients’ experience of poor sleep quality. Other PSG findings reported in FMS include decreased total sleep time,
decreased delta sleep, and decreased REM sleep percentages27.
FMS patients also are highly prone to sleep-disordered breathing resulting in inspiratory airflow limitation; this
was found in 27 of 28 FMS patients60. Poor sleep has been strongly associated with greater pain55;61 and fatigue11;53 in
FMS. Sleep quality was found to have a predictive relationship to pain in a longitudinal study of 492 FMS patients55.
Conversely, improving sleep quality has decreased pain and fatigue in FMS patients and has been viewed as a barometer
for clinical symptom management16;34. Rates of sleep apnea/hypopnea in women with FMS have been reported to be
approximately 19 to 25%62. Yet identification and treatment of sleep disorders in FMS patients, such as obstructive sleep
apnea (OSA) or upper airway resistance, has not consistently led to improvement in overall FMS symptoms30.
Additionally, the extent to which various sleep disorders may be considered a part of the underlying ANS dysfunction
posited for FMS remains unknown. Other investigators have found that quantified-delta EEG power, auditory arousal
thresholds, and urinary free cortisol largely failed to distinguish FMS and control subjects, but HRV analyses showed
more promise, as they suggested both increased sympathetic activity and decreased complexity of autonomic nervous
system function in FMS63. Therefore, further investigation into the role of sleep microstructure in the predisposition to or
onset of FMS symptoms is warranted.
Fatigue and FMS
Fatigue, defined as weariness caused by exertion, is a sensation of decreased vitality that disrupts activities of daily
living64. It can vary from general lethargy to a specific work-induced burning in particular muscles and may be physical
and/or mental. Fatigue has been described in qualitative studies as a highly debilitating symptom of FMS and a constant,
inescapable burden that isolated patients from family and community65;66. Zautra et al.64 found that 90 FMS patients
reported significantly more pain and fatigue than 89 rheumatoid arthritis or 76 osteoarthritis patients. In studying
predictors of fatigue in 105 FMS patients, Nicassio et al.8 reported that poor sleep quality accounted for a significant,
positive relationship between pain and fatigue. FMS patients have described a vicious cycle of pain and non-restful sleep
underlying their experience of fatigue65;67.
Pain and FMS
Pain is central to the detection of FMS. The American College of Rheumatology guidelines for diagnosis of FMS
require widespread aching for at least 3 months and 11 out of 18 possible tender points56;68. Tender points are elicited by
applying 4 kg manual pressure to those 18 predefined points30. Functional magnetic resonance imaging (fMRI) studies
have shown activation patterns in FMS patients’ brains comparable to their reported pain, even if the stimulus was light
pressure32;37;69. Cook et al.37 used fMRI to compare 9 FMS patients to 9 controls and found significantly greater activity in
prefrontal, supplemental motor, insular, and anterior cingulate cortices. Wood et al.70 studied 11 FMS patients as compared
to 11 controls with fMRI and found that FMS patients exhibited an abnormal dopamine response to painful stimuli. They
observed a positive relationship between amount of dopamine released in response to pain, and a patient’s perceived pain
intensity70.
Julien et al.68 hypothesized that FMS pain may be a deficit of endogenous pain inhibition, i.e., ineffective
descending control mechanisms. They compared 30 FMS patients to 30 chronic low back pain patients and 30 controls; the
FMS group differed significantly from the other groups in that their perception of pain did not diminish during the
descending as compared to the ascending cold stimulation sessions. Stress has been viewed as a key variable in pain

31

FIBROMYALGIA
perception; low-grade mental stress significantly increased pain perception for 29 FMS patients in comparison to 35
controls in one study38. The underlying mechanism is unknown but an animal-model study implicated the HPA axis in
altered cell-signaling71. The investigators speculated that even relatively low-level mental stress might precipitate a longlasting hyperalgesic reaction in FMS patients.
Cytokines and Sleep
Cytokines are polypeptides that act as chemical messengers between immune cells (among others); cytokines are
critical to cell growth, repair, and modulation of pro- and antiinflammatory immune responses7. Interactions among the
HPA axis, the SNS, and cytokines help regulate sleep, stress responses, pain perception, and fatigue7; they are also affected
by sleep. Chronic insomnia was associated with a shift of IL-6 and tumor necrosis factor (TNF) secretion from patterns of
nighttime to daytime elevations in 11 insomniacs compared to 11 controls72. Sleep deprivation was found to reduce natural
killer cell activity in 45 volunteers in a within-subject study73. It was found in a within-subject study (n=30) that sleep
deprivation was associated with altered monocyte proinflammatory cytokine responses, and with significantly increased
production of IL-6 and TNF-α74. A followup study by those researchers explored differences by gender; sleep loss was
again associated with altered monocyte pro-inflammatory cytokine responses, with 11 females showing significantly more
cellular immune activation than 15 males75.
IL-1 and TNF-α have been related to symptoms associated with sleep deprivation, such as pain and fatigue76-78;
both cytokines are somnogenic and enhance electroencephalograph (EEG) slow waves. IL-1 and TNF-α increase the
duration of NREM sleep and reduce REM sleep, yet IL-1 also causes fragmentation of NREM sleep in a dose-dependent
way78. Suggested NREM-promoting substances are IL-2, acidic fibroblast growth factor, interferon (IFN)-α, epidermal
growth factor, neurotrophins, nitric oxide, adenosine, prostaglandin P2, and growth hormone releasing factor (GHRH);
however, evidence for their role in sleep is still accumulating76. Cytokines thought to inhibit NREM sleep include; IL-1,
IL-4, IL-10, IL-13, insulin-like growth factor, transforming growth factor-β, the soluble IL-1, and TNF receptors59;76.
Research on the relationships among cytokine patterns and sleep patterns continues to develop and the proposed study has
the potential to contribute to knowledge development in this area.
Cytokines and FMS
Alterations in various cytokine levels have been reported in FMS patients, but this is a rapidly developing field,
with various study methods and contradictory results being reported19. Plasma IL-1 receptor antibody (IL-1ra) and IL-8
levels were significantly higher in 56 FMS patients as compared to 56 age- and gender-matched controls in an early pilot
study18. Skin biopsies of 53 FMS patients were compared to those of 10 age- and gender-matched controls; IL-1β (38%),
IL-6 (27%) and TNF-α (32%) were detected in FMS patients but not in controls79. Initial plasma TNF-α and IL-8 levels
were elevated, but not IL-6, in 20 FMS patients compared to 80 controls in a longitudinal study80. Those authors reported
that IL-8 levels correlated with perceived pain intensity, but only at the end of a 6-month study, when it decreased along
with pain reports; they did not find a significant difference in IL-10 levels. Higher IL-8 levels, but not IL-1 or IL-6, were
seen in 81 FMS patients as compared to 32 controls81. Increased IL-6 levels in 6 FMS patients were found during a
tryptophan depletion study, but those levels were decreased in 11 other FMS patients and all 17 controls82. They postulated
the existence of a select subgroup of FMS patients; this might imply more than one etiology for FMS, or perhaps genetic
variations in cytokine responses. Togo et al.83 reported 3 significant findings; in contrast to 9 controls, 7 FMS patients had
frank increases in nighttime antiinflammatory cytokine IL-10 secretion, they did not have compensatory bursting of proinflammatory cytokines IL-8, IL-1β and TNF-α, and even during the day, the ratio of pro- to antiinflammatory cytokines
was reduced relative to controls.
It has been suggested that there is an imbalance in FMS patients in favor of sleep-disturbing antiinflammatory
cytokine responses during sleep84. Yet, other researchers reported findings in contradiction to Togo et al.83; in 40 patients
with widespread pain, 26 of whom had FMS (vs. 40 age- and gender-matched controls), they found lower mRNA levels
for the anti-inflammatory cytokines IL-4 and IL-10, no significant increase in proinflammatory cytokines, and no
significant correlations among cytokine levels and fatigue in FMS patients85. They also noted that cytokines are key
elements in the induction and maintenance of pain, and posited that an imbalance of pro- and antiinflammatory cytokine
levels may be a significant variable in FMS pain sensitivity86.
The authors of a recent integrative review of cytokines in FMS concluded that there are discrepancies regarding
whether pro- or antiinflammatory cytokines are elevated or reduced in FMS, and whether or not they correlate with FMS
symptoms87. They call for pursuing this potentially promising line of research, using multiplex cytokine measurement
platforms, which might offer a more complete picture of the pro/anti inflammatory balance among cytokine levels.
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VIII. PRELIMINARY PROGRESS/DATA REPORT
If available.
Ms. McNallen has gained invaluable experience in working collaboratively with interdisciplinary teams through various
exposures and experiences in research at the VCU School of Nursing. The study described below highlights her
experiences in the design and implementation of a biobehavioral study, including data collection, measurement, database
development, and dissemination of study results.
Actigraphy and Patient Movement
This was a substudy of a larger study, NIH/NINR R01 NR009506, entitled “Sedation effects in mechanically
ventilated patients” (SAVE Study) with Dr. Grap, principal investigator (PI). The specific aim of this study was to
evaluate, in a laboratory setting, actigraphic measures of a variety of simulated activity types (calm/sedated, restless,
agitated states). A sample of 30 participants was drawn from volunteers 18 years of age or older who responded to posted
brochures or flyers. Exclusion criteria included neuromuscular disorders that might result in abnormal movement (e.g.,
Parkinson’s disease) or decreased levels of movement (e.g., paralysis), severe sensory limitations, or inability to speak
English. Data were collected to quantify the actigraphic pattern associated with different levels of observed movement. As
a graduate research assistant (GRA) working for the SAVE study, Ms. McNallen developed and submitted the substudy
protocol to the VCU Institutional Review Board (IRB), prepared all study measures and procedures, and wrote the
operations manual. The study was approved by the VCU IRB on October 28, 2008; participant recruitment, enrollment and
data collection were completed on May 15, 2009. The applicant set up and maintained the study database in collaboration
with the SAVE study research team (M.J. Grap [PI]; V.A. Hamilton [project director]; J. Ketchum [Biostatistician]). Ms.
McNallen performed all data entry and management and collaborated extensively in data analysis. This experience
provided invaluable experience and skills building related to conducting and completing a research study as well as
training in the use of instruments that may be used in her proposed study. Collaborative experience in research
methodology and dissemination continues; an abstract on the SAVE actigraphy study was presented at the 2010 Southern
Nursing Research Society conference. A manuscript (Grap, Hamilton, McNallen, Best, Ketchum, Wetzel, & Arief) has
been accepted for publication in Heart and Lung.
Self-efficacy, Stress, Immunity, and Symptoms of Fibromyalgia
Ms. McNallen has worked as a GRA for this ongoing study since its inception in October 2009. She has worked
closely with the PI, Dr. Victoria Menzies, and is responsible for participant recruitment, scheduling, study preparation,
data collection, and data management to date. She developed the study Protocol Manual, internal documents, and
procedures for the study used by the undergraduate research assistants assigned to the study. She has acquired extensive
experience with the FMS population, made contacts within the FMS support community, and also acquired hands-on
experience with administering many of the study measures she will use in this proposed study.

IX. RESEARCH METHOD AND DESIGN
Include a brief description of the project design including the setting in which the research will be conducted and
procedures. If applicable, include a description of procedures being performed already for diagnostic or treatment
purposes.
Using a single stage cross-sectional design, the primary aim of this study is to compare 2 groups, 25 women with and 25
women without FMS, who are referred for sleep studies at the VCU Center for Sleep Medicine on the following variables:
ANS activity (COMPASS and HRV); perceived stress (PSS); sleep quality (PSG and PSQI); immune function (17-plex
cytokines); and fatigue (BFI). A secondary aim is to explore the relationships among the above variables within each group
of participants. Also, within the FMS group these variables will be correlated with pain (BPI). The third aim is to assess
the validity of the COMPASS by comparing it to measures of HRV and sleep indices (number of arousals and sleep
latency).
Table 1: Key study variables and their measures
Variable
Measure
Type
FMS

Demographic data

Questionnaire
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ANS activity

COMPASS
Heart rate variability (HRV)

73- item scale
Sleep study

Immune Function
Stress
Sleep Quality

Plasma 17-plex cytokines
Perceived Stress Scale (PSS)
Pittsburgh Sleep Quality Index (PSQI)
Polysomnography (PSG)
Brief Fatigue Inventory (BFI)
Brief Pain Inventory (BPI)

8 ml blood sample
10-item scale
19-item scale
Sleep study
10-item scale
11-item scale

Fatigue
Pain (in FMS only)

Setting
The VCU Center for Sleep Medicine is the setting for this study. All recording and monitoring equipment is
enclosed in a centrally located control room separate from 5 testing bedrooms. The center has monitoring equipment and a
computer system that allow completely digital sleep recordings. The control room is staffed by professional technicians
who greet and prepare scheduled patients in the early evening, and monitor the sleep studies continuously through the
night. Preparation of the patient for PSG normally takes approximately an hour for all monitoring equipment to be applied.
Dr. David Leszczszyn, the medical director of this facility (see letter of support) will assist with access to study
participants. The VCU Center for Sleep Medicine saw 861 patients in 2007, with 52% (463) of these being female. The
average female age was 50; 57% were African American, 41% Caucasian, and 2% Hispanic or other/unknown. Of these,
10% (46) may be estimated to have a diagnosis of FMS.
Sample
A total of 50 women, 25 with a recorded medical diagnosis of FMS, and 25 without such a diagnosis, will be
recruited. The sample will include participants aged 35 to 65, without rheumatologic comorbidities, and not pregnant.
The participants recruited who do not have a diagnosis of FMS will be queried for the presence of chronic widespread pain
to avoid including undiagnosed FMS persons within the comparison group.
Table 2: Inclusion/exclusion criteria for proposed study
Inclusion Criteria
Exclusion Criteria
Aged 35 to 65
Female
For FMS group:
For Comparison group:
Referral to Sleep Disorders Center
English literacy
Ability to complete questionnaires
Able to participate in sleep study

Pediatric patients
Males
Rheumatologic conditions, i.e. RA, SLE, or Sjogren’s
disease.
Chronic widespread pain or rheumatologic conditions that
may be confounded with FMS.
Pregnancy
Major communicative disorder
Unable to sleep alone at sleep study

Measures
A demographic and health history questionnaire will be used to obtain information regarding age, height, weight,
race/ethnicity, partner status, length of FMS diagnosis, education, socioeconomic status, psychiatric history, medical comorbidities, and medication history. This is completed by the potential participant upon arrival at the VCU Center for
Sleep Medicine. Sleep environment, usual bedtime, symptom management measures employed by the participant, and
blood pressure, pulse and respirations will also be recorded. History of any suspected or diagnosed sleep disorders will be
obtained. Menstrual status, determined by the date of the last menstrual period, will be recorded since 72% of premenopausal women report worsening of FMS symptoms prior to menstruation. Pregnancy and menopause have also been
reported to exacerbate symptoms88.
ANS function will be measured with the Composite Autonomic Symptoms Scale (COMPASS), a 73-item
multidimensional questionnaire that takes approximately 30 minutes to complete89. It does not directly measure ANS
function, but assesses orthostatic, secretomotor, sexual dysfunction, urinary, gastrointestinal, pupillomotor, vasomotor,
reflex syncope, and sleep functions. Symptoms from these 9 domains have been found to be consistent with autonomic
dysfunction. The highest possible score for women is 170. Mean score for the initial sample of healthy control women was
47.2 ± 11.6; women with neurogenic autonomic failure had a mean score of 57.4 ± 13.989. Since no validated self-report
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autonomic questionnaire existed prior to COMPASS, it could not be tested for concurrent validity; the authors tested it
against the Composite Autonomic Scoring Scale (CASS) for criterion validity89. The CASS has been reported to be
sensitive and specific for detecting autonomic symptomatology90.
The COMPASS has since been used to study FMS patients, where it was found to significantly correlate with the
Fibromyalgia Impact Questionnaire28. Mean score for FMS patients in that study (54.6 ± 20.9) differed significantly from
healthy controls (9.5 ± 10.2). It has been used to study patients with primary Sjogren’s syndrome in relation to HRV91.
Those investigators found a modest correlation between COMPASS and decreased HRV that did not attain statistical
significance. Patients with chronic fatigue syndrome (CFS) have also been studied with COMPASS and HRV
measurements; those researchers found significantly higher COMPASS scores in CFS patients as compared to healthy
controls92. They also reported a strong, significant correlation between low-frequency HRV and higher COMPASS scores.
ANS function will also be evaluated using HRV, derived from the continuous ECG recording that is a customary
39
part of PSG throughout the night. Staud stated that, “although not specific for FM(S), ANS dysfunction can be

readily determined by HRV analysis requiring only computer analysis of ECG recordings by commercially
available software”. He concluded that ANS dysfunction as assessed by HRV analysis is a useful biomarker, and may
even become part of FMS diagnostic criteria in the future. As noted earlier, FMS is characterized by persistent ANS
hyperactivity at rest, yet hyporeactivity during stress (the ceiling effect). FMS patients have displayed higher resting heart
rates and lower HRV than controls; in addition, power spectral analysis of their HRV variability was positively correlated
with their perceived stress and pain49. One clinical trial of HRV biofeedback in FMS patients indicated a trend suggestive
of improvements in sleep and pain93.
Perceived stress will be measured with the 10-item Perceived Stress Scale (PSS). It has been used for more than 16
years in a variety of patient populations and in many health-related contexts94. It measures the frequency of stressful events
over a month’s time, perceived control, the degree to which situations are perceived to be stressful, and ability to cope17.
Because it is a global measure of perceived stress, it does not measure the same concept as psychological distress. It has
been reported to have a reliability coefficient for the 10-item version of α=0.9194. The authors also reported that the 10item PSS met standards of construct validity and criterion-related validity and reflected a unidimensional construct of
stress.
Sleep quality will be measured with the Pittsburgh Sleep Quality Index (PSQI), a 19-item questionnaire that
assesses sleep quality and disturbances over a one-month interval. The items generate 7 component scores: sleep quality,
sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime
dysfunction. Each of the component scores is weighted equally on a scale of 0 to 3, 0 indicating no difficulty and 3
indicating severe difficulty. The component scores are then summed to yield a global PSQI score, ranging from 0 to 21.
Higher scores indicate worse sleep quality; a global PSQI score > 5 is consistent with poor sleep quality. The overall PSQI
global score correlation coefficient for test-retest reliability was reported to be 0.87; a global score >5 resulted in a
sensitivity of 98.7 and specificity of 84.4 as a marker for sleep disturbances in insomnia patients versus controls95. It has
been used to assess sleep quality in FMS patients in several studies 17;54.
Sleep quality will also be measured with polysomnography (PSG), an array of physiologic measures to study sleep
duration and quality, including central and occipital EEG, eye movement monitoring, muscle tension in several locations,
ECG, airflow, respiratory rate, blood oxygen saturation, limb movements, and expired CO2. PSG has been in use for sleep
studies since 1968, and has continually developed and evolved with changes in technology96. PSG is performed in an
outpatient sleep laboratory overnight, with technicians monitoring patient status and equipment. The entire battery of tests
is arrayed on a computer monitor and sleep stages (wake, stages 1-3 NREM, and REM) are visually scored for 30-second
epochs according to the criteria of Rechtschaffen and Kales96. A neurologist board-certified in sleep medicine reads and
interprets results. PSG is a major diagnostic clinical tool and has been employed in many studies of FMS and sleep56;97.
Fatigue will be measured using the Brief Fatigue Inventory (BFI)98, a 9-item scale that taps into a single dimension
of fatigue severity and the interference fatigue creates in daily life. The BFI is a clinically validated tool used to assess
cancer-related fatigue and its impact on daily functioning. The BFI uses simple numeric rating scales from 0 to 10 that are
easy to understand. On the BFI, severe fatigue can be defined as a score of 7 or higher. The BFI has demonstrated
excellent reliability in clinical trials, ranging from 0.82 to 0.97 99. Estimated time for completion of the BFI is 5 minutes.
Pain will be measured using the Brief Pain Inventory (BPI)100, an 11-item pain assessment tool that has wellestablished reliability and validity for adult patients with no cognitive impairment in trajectory studies of cancer and its
symptoms101. The BPI assesses current pain, average severity of pain, the amount of pain in the past 24 hours, and the
impact of pain on daily functions. Estimated time for completion of the BPI is 5 minutes. The arithmetic mean of the 4
severity items will be used as a measure of pain severity, and the arithmetic mean of the 7 interference items will be used
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as a measure of pain interference. In widespread testing, the Cronbach’s α reliability has ranged from 0.70 to 0.9199.
Cytokine samples will be collected via 8-milliliter blood samples obtained by venipuncture using CPT cell
preparation tubes with sodium heparin for plasma assay. Samples will be analyzed using the Bio-Plex® Human 17-Plex
(Bio-Rad: Hercules, CA) multiplex assay system. This system permits simultaneous analyses of up to 100 different
biomolecules in a single microplate well. Daily system calibration and assay validation are performed using
standardization methods developed by the manufacturer. Bio-Plex® offers greatly improved sensitivity (10 pg/ml),
reliability, recovery, and reproducibility in comparison to conventional enzyme-linked immunosorbent assays (ELISAs).
The standardized 17-Plex kit includes coupled beads, detection antibodies, and standards for the detection of IL-1β, IL-2,
IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, granulocyte colony stimulating factor (G-CSF), granulocytemacrophage colony stimulating factor (GM-CSF), interferon-gamma (IFN-γ), monocyte chemoattractant protein-1 (MCP1), macrophage inflammatory protein-1β (MIP-1β), and tumor necrosis factor alpha (TNF-α).
Procedures
Recruitment and enrollment. The student will conduct a preliminary test of all study procedures during fall 2010,
prior to participant recruitment to ensure that all procedures, equipment and data collection techniques are operational.
Potential participants will be pre-selected based on the VCU Center for Sleep Medicine database of women, both those
diagnosed with FMS, and those without such a diagnosis. Those with a diagnosis of FMS will be screened for the presence
of exclusion criteria, such as a concurrent diagnosis of SLE. Those women without a diagnosis of FMS will be screened
for the presence of chronic widespread pain that might be indicative of an undiagnosed FMS condition. The student will
make rounds at the VCU Center for Sleep Medicine to evaluate patients as potential study participants based on their
medical and sleep histories, invite study participation from those who meet eligibility criteria, conduct all informed
consent processes, and screen and enroll all participants who consent to participate in the study.
Data collection procedures. Psychometric data obtained for study purposes will not affect the participant’s care;
clinical data obtained from PSG or intake interviews will be used in clinical diagnosis and/or management of any sleep
disorder detected, as per VCU Center for Sleep Medicine institutional protocol. Once the participant has been screened,
consented, and is enrolled in the study, descriptive data concerning participant demographics will be collected from
medical records and patient interviews using the demographic and health history form. All data collection will occur at the
VCU Center for Sleep Medicine. Once included in the study, and after completion of the demographic and health history
form, each participant will receive an appointment for the sleep study at the VCU Center for Sleep Medicine.
Each study participant will meet the student at the VCU Center for Sleep Medicine 90 minutes prior to her
scheduled sleep study. For purposes of sleep study protocol, patients usually arrive at either 7:30 or 8:30 pm and stay until
6 am; therefore, for purposes of the proposed study, participants will be asked to arrive either at 6:00 p.m. or 7:00 p.m.,
depending upon their appointment time. During this time, the study participant will complete the COMPASS, the PSS, the
PSQI, the BFI, and the BPI. After questionnaires have been completed, the student will perform venipuncture on a
participant’s accessible arm vein to collect an 8-milliliter blood sample into CPT cell preparation tubes with sodium
heparin. Following completion of study data collection, each participant will be compensated for their time with a $25 gift
card.
VCU Center for Sleep Medicine staff managing patient care will evaluate the patient’s comfort and stability in a
routine manner while conducting the sleep study. The sleep study will not vary in any way from established VCU Center
for Sleep Medicine institutional protocols. Technicians initiate and monitor the PSG throughout the night; a neurologist,
board certified in sleep medicine, interprets PSG findings at a later time. If patients require treatment during the night, such
as use of a continuous positive airway pressure (CPAP) machine for sleep apnea, treatment will be initiated per VCU
Center for Sleep Medicine protocol. Evaluation, diagnosis and treatment based on sleep study results will be conducted by
the participant’s physician.
The blood sample will be placed in an appropriate cold-pack biohazard container for transport to the CBCR
laboratory at the VCU School of Nursing, where it will be stored and analyzed. All blood samples will be centrifuged for
separation of plasma; specimens will be aliquoted, frozen, and stored at -70° C until all samples have been collected.

X. PLAN FOR CONTROL OF INVESTIGATIONAL DRUGS, BIOLOGICS, AND DEVICES.
For investigational drugs and biologics: IF IDS is not being used, attach the IDS confirmation of receipt of the
management plan.. See item #11 on Initial Review form.
For investigational and humanitarian use devices (HUDs): Describe your plans for the control of investigational
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devices and HUDs including: (1) how you will maintain records of the product’s delivery to the trial site, the inventory
at the site, the use by each subject, and the return to the sponsor or alternative disposition of unused product(s); (2)
plan for storing the investigational product(s)/ HUD as specified by the sponsor (if any) and in accordance with
applicable regulatory requirements; (3) plan for ensuring that the investigational product(s)/HUDs are used only in
accordance with the approved protocol; and (4) how you will ensure that each subject understands the correct use of
the investigational product(s)/HUDs (if applicable) and check that each subject is following the instructions properly
(on an ongoing basis).
N/A
XI. DATA ANALYSIS PLAN
For investigator–initiated studies.
Data analysis plan
Statistical analyses will be performed using JMP 8.0 or higher, and significance set at α ≤ 0.05. Descriptive
statistics of the 2 groups will be reported and compared, with means and standard deviations for continuous data, and
frequency distributions and percentages for ordinal or categorical data. The normality for all continuous variables will be
examined to assess the need for a transformation (e.g., the cytokines are typically log-transformed). For the demographic
variables, differences between the groups will be assessed using 2-sample t-tests for continuous data and Chi-square for
ordinal or categorical data.
To test the Aim One hypotheses, 2-sample t-tests will be used to test for significant group differences in the study
variables, ANS activity (COMPASS and HRV), perceived stress (PSS), sleep quality (PSG and PSQI), immune function
(17-plex cytokines), and fatigue (BFI). The normality for all continuous variables will be examined to assess the need for
transformations. It is expected that the cytokines will be analyzed following log transformations.
To test the Aim Two hypotheses, Pearson’s correlation coefficients will be calculated to determine the
relationships among ANS activity (COMPASS and HRV), perceived stress (PSS), sleep quality (PSG and PSQI), immune
function (17-plex cytokines), and fatigue (BFI) within each group. Also, within the FMS group, these above variables will
be correlated with pain (BPI). For Pearson’s correlation coefficient to be used, several conditions must be met: variables
must be quantitative with no restriction on their level of precision; the variables must have a linear relationship; and the
variables must be normally distributed102. The normal distribution of all the above continuous variables will be examined
to assess the need for a transformation to meet these assumptions. Linearity will also be assessed.
To test the Aim Three hypothesis, Pearson’s correlation coefficients will be calculated to determine the
relationships among COMPASS scores, HRV, and selected sleep indices (number of arousals and sleep latency).

XII. DATA AND SAFETY MONITORING
• If the research involves greater than minimal risk and there is no provision made for data and safety monitoring
by any sponsor, include a data and safety-monitoring plan that is suitable for the level of risk to be faced by
subjects and the nature of the research involved.
• If the research involves greater than minimal risk, and there is a provision made for data and safety monitoring
by any sponsor, describe the sponsor’s plan.
• If you are serving as a Sponsor-Investigator, identify the Contract Research Organization (CRO) that you will be
using and describe the provisions made for data and safety monitoring by the CRO. Guidance on additional
requirements for Sponsor-Investigators is available at http://www.research.vcu.edu/irb/wpp/flash/X-2.htm
Data and Safety Monitoring Plan
The proposed project is an observational study, not a clinical trial. The study investigator is available 24 hours a
day by cell phone; this number is provided to participants. The study investigator will meet monthly with the PI
(dissertation chair) to monitor for safety issues. In addition, the study process will be reviewed for unexpected occurrences
or alterations in clinical conditions. Any changes will be examined for their relationship to the project protocol. Reports of
these chair meetings will be reviewed at the full progress meetings of the Dissertation Committee.
Because the planned project involves minimal risk, no adverse events are expected to occur as a direct result of
participant participation. However, should any event occur that might be related to study participation, the study
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investigator will assume responsibility for notification of the designated care providers and any referral for recommended
treatment, as well as notification of the VCU IRB. Adverse event reporting forms and procedures are available on-line at:
http://www/orsp.vcu.edu/irb.
XIII. MULTI-CENTER STUDIES
If VCU is the lead site in a multi-center project or the VCU PI is the lead investigator in a multi-center project,
describe the plan for management of information that may be relevant to the protection of subjects, such as reporting
of unexpected problems, project modifications, and interim results.

N/A
XIV. INVOLVEMENT OF NON-VCU INSTITUTIONS/SITES (DOMESTIC AND FOREIGN)
1. Provide the following information for each non-VCU institution/site (domestic and foreign) that has agreed to
participate:
• Name of institution/site
• Contact information for institution/site
N/A
2. For each institution, indicate whether or not it is “engaged” in the research (see OHRP’s guidance on
“Engagement of
Institutions in Research” at http://www.hhs.gov/ohrp/humansubjects/guidance/engage08.html.)
N/A
3. Provide a description of each institution’s role (whether engaged or not) in the human subjects research, adequacy
of the facility (in order to ensure human subject safety in the case of an unanticipated emergency), responsibilities of
its agents/employees, and oversight that you will be providing in order to ensure adequate and ongoing protection of
the human subjects. You should only identify institutions that have agreed to participate. If additional institutions
agree to participate at a later time, they must be added by amendment to the protocol.
N/A
4. For each institution that is “engaged” provide an OHRP Federalwide Assurance (FWA) # if: (1) the research is not
exempt, AND (2) the research involves a DIRECT FEDERAL award made to VCU (or application for such).
NOTE: Additional guidance at http://www.research.vcu.edu/irb/wpp/flash/XVII-6.htm, and
http://www.research.vcu.edu/irb/wpp/flash/XVII-11.htm.
N/A
XV. INVOLVEMENT OF INDEPENDENT INVESTIGATORS
INDEPENDENT INVESTIGATOR: an individual who is acting independently and not acting as an agent or employee of
any institution or facility while carrying out his or her duties in the research protocol. Additional guidance at
http://www.research.vcu.edu/irb/wpp/flash/XVII-15.htm.
ENGAGEMENT IN RESEARCH: An independent investigator becomes "engaged" in human subjects research when
he/she (i) intervenes or interacts with living individuals for research purposes; or (ii) obtains individually identifiable
private information for research purposes [45 CFR 46.102(d)-(f)]. See OHRP’s guidance on “Engagement of
Institutions in Research” at http://www.hhs.gov/ohrp/humansubjects/guidance/engage08.html.
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1. Provide a list of independent investigators.
2. For each independent investigator indicate whether or not he/she is “engaged” or “not engaged” in the research
3. For each independent investigator who is “engaged”: (1) describe his/her role with human subjects/identifiable
human data, AND (2) describe YOUR oversight of his/her involvement.
N/A
NOTE: If an independent investigator is “engaged,” and the research is (1) not exempt AND (2) involves a DIRECT FEDERAL
award made to VCU (or application for such), the independent investigator must sign a formal written agreement with VCU
certifying terms for the protection of human subjects. For an agreement to be approved: (1) the PI must directly supervise all
of the research activities, (2) agreement must follow the ORSP template, (3) IRB must agree to the involvement of the
independent investigator, AND (4) agreement must be in effect prior to final IRB approval.
XVI. HUMAN SUBJECTS INSTRUCTIONS (Be sure to use the sub-headings under A-I)
ALL sections of the Human Subjects Instructions must be completed with the exception of the section entitled
“Special Consent Provisions.” Complete that section if applicable.
A. DESCRIPTION
Provide a detailed description of the proposed involvement of human subjects or their private identifiable data in the
work.
The study will involve 50 female participants ages 35 or older, 25 with fibromyalgia and 25 without fibromyalgia.
Participants must meet the study criteria outlined below. They will be recruited using study advertisements and participant
referrals. Eligible participants will be asked to sign the consent, complete demographic and psychosocial measures, and
allow a one-time venous blood draw, the evening of their scheduled sleep study at the VCU Center for Sleep Medicine.
B. SUBJECT POPULATION
Describe the subject population in terms of sex, race, ethnicity, age, etc., and your access to the population that will
allow recruitment of the necessary number of participants. Identify the criteria for inclusion or exclusion of any
subpopulation and include a justification for any exclusion. Explain the rationale for the involvement of special cases
of subjects, such as children, pregnant women, human fetuses, neonates, prisoners or others who are likely to be
vulnerable. If you plan to allow for the enrollment of Wards of the State (or any other agency, institution, or entity),
you must specifically request their inclusion and follow guidance on Wards and Emancipated Minors in the VCU IRB
Written Policies and Procedures (specifically WPP#: XV-3) available at
http://www.research.vcu.edu/irb/wpp/flash/XV-3.htm.
The sample will consist of 50 female participants, 25 diagnosed with fibromyalgia and 35 without fibromyalgia, who meet
inclusion criteria and complete the study.
Inclusion Criteria: a) ages 35 and older; b) female; c) diagnosis of fibromyalgia confirmed by the patient’s
primary physician by half the sample; d) no known major psychiatric or neurological conditions that would interfere with
study participation; e) able to speak and read standard English; f) a minimum of a 6th grade education level; and g) an
ability to understand and sign the consent form and understand and complete the pencil and paper assignments.
Exclusion Criteria: are (a) presence of other systemic rheumatologic conditions such as rheumatoid arthritis,
systemic lupus erythematosus, and/or Sjogren's Disease; (b) history of epilepsy; (c) any present psychiatric disorder
involving a history of psychosis (e.g., schizophrenia, schizoaffective disorder; schizophreniform disorder, delusional
disorder, etc.); (d) being immunocompromised; (e) receiving corticosteroid treatments; or (f) being pregnant.
C. RESEARCH MATERIAL
Identify the sources of research material obtained from individually identifiable living human subjects in the form of
specimens, records, or data. Indicate whether the material or data will be obtained specifically for research purposes
or whether use will be made of existing specimens, records, or data.
Data will be collected from research instruments given to the study participants by the study investigator. In addition, FMS
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participants will be asked to provide documentation confirming FMS diagnosis unless this is already in the VCUHS data
base. The results of the sleep study will be obtained by the study investigator. Blood samples will be collected by the study
investigator via venipuncture into 8-milliliter CPT cell preparation tubes with sodium heparin. All data will be obtained
specifically for research purposes.
D. RECRUITMENT PLAN
Describe in detail your plans for the recruitment of subjects including: (1) how potential subjects will be identified
(e.g., school personnel, health care professionals, etc), (2) how you will get the names and contact information for
potential subjects, and (3) who will make initial contact with these individuals (if relevant) and how that contact will
be done. If you plan to involve special cases of subjects, such as children, pregnant women, human fetuses, neonates,
prisoners or others who are likely to be vulnerable, describe any special recruitment procedures for these populations.
Participants will be recruited using study advertisements (flyers and brochures) distributed in print (see Appendix
C) at the VCU Center for Sleep Medicine. Dr. David Leszczyszyn, MD, PhD, the medical director (see letter of support,
Appendix D) will assist with access to the project settings.
Participants may self-identify as potential participants by responding to advertisements and calling the study
investigator at her office telephone number or contacting her through an email address (each identified in advertising
materials). The study investigator will explain the study to the potential participant who will be screened based upon
inclusion and exclusion criteria. If she meets the study criteria and desire to participate, an appointment will be made for
her to meet with the study investigator at a convenient time. At this initial meeting, the study investigator will review the
study, obtain informed consent, and conduct and conduct the data collection visit. The data collection visit will be
conducted in a private room at the VCU Center for Sleep Medicine. Following consent and enrollment, the data collection
visit, which includes administration of the measurement tools and collection of the blood sample, should take no longer
than 90 minutes.
E. POTENTIAL RISKS
Describe potential risks whether physical, psychological, social, legal, or other and assess their likelihood and
seriousness. Where appropriate, describe alternative treatments and procedures that might be advantageous to the
subjects.
Venipuncture involves potential small risk of ecchymosis or infection at the site. As the questionnaires do not involve any
sensitive data, no risk to the subjects is anticipated related to completion of questionnaires.

F. RISK REDUCTION
Describe the procedures for protecting against or minimizing potential risk. Where appropriate, discuss provisions
for ensuring necessary medical or professional intervention in the event of adverse events to the subjects. Also, where
appropriate, describe the provisions for monitoring the data collected to ensure the safety of subjects.
As part of the process involved in obtaining written informed consent, participants will be given a copy of the informed
consent form. Venipuncture will be performed by the study investigator using aseptic technique. The PI and the study
investigator are both licensed, registered nurses. Because the nature of the survey questions is not sensitive, this poses
almost no risk to participants. Contact information for the PI and the study investigator is provided on the consent form.
G. ADDITIONAL SAFEGUARDS IF ANY PARTICIPANTS WILL BE VULNERABLE
Describe any additional safeguards to protect the rights and welfare of participants if you plan to involve special cases
of subjects, such as children, pregnant women, human fetuses, neonates, prisoners or others who are likely to be
vulnerable. Safeguards to protect the rights and welfare of participants might relate to Inclusion/Exclusion Criteria:
(“Adults with moderate to severe cognitive impairment will be excluded.” “Children must have diabetes. No normal
controls who are children will be used.”) Consent: (“Participants must have an adult care giver who agrees to the
participant taking part in the research and will make sure the participant complies with research procedures.”
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“Adults must be able to assent. Any dissent by the participant will end the research procedures.”) Benefit:
(“Individuals who have not shown benefit to this type of drug in the past will be excluded.”).
All participants shall be able to understand English and able to assent to participate. Any dissent or withdrawal of consent
by the participant will end the research procedure.
H. CONFIDENTIALITY
Describe how the confidentiality of data collected as part of this project will be protected including pre-screening data
(e.g., physical controls on the data; access controls to the data; coding of data; legal controls, such as a Federal
Certificate of Confidentiality; statistical methods; or reporting methods).
Confidentiality of participant data is the primary safety-related issue in this study. Participants’ identities will be protected.
Each data record will be assigned an arbitrary code number by the study investigator and then identifying information will
be removed from the data record and attached to the consent form, which will be kept in a locked file accessible only by
the study personnel. All laboratory data and sleep study results will be blindly and anonymously coded.
I. PRIVACY
Describe how the privacy interests of subjects will be protected where privacy refers to persons and their interests in
controlling access to themselves, and assess their likely effectiveness. Identify what steps you will take for subjects to
be comfortable: (1) in the research setting and (2) with the information being sought and the way it is sought.
Study participants and information will only be accessible to the study investigator and the PI who will maintain
participant privacy and ensure clinical acumen. Each study visit will be conducted in a private room to ensure participants’
privacy.
J. RISK/BENEFIT
Discuss why the risks to subjects are reasonable in relation to the anticipated benefits to subjects and in relation to the
importance of the knowledge that may reasonably be expected to result. If a test article (investigational new drug,
device, or biologic) is involved, name the test article and supply the FDA approval letter.
This study has the potential to make a significant contribution to the literature in the areas of chronic illness and symptom
management, healthcare research, and to provide scientific support for relationships among psychoneuroimmunological
parameters in persons diagnosed with FMS. If it is found that there are significant correlations among cytokine production
patterns, ANS symptoms, perceived stress, and symptoms of pain, fatigue, and sleep disturbance, this information will help
in the design of nursing interventions for managing sleep disturbance and other symptoms related to this disorder, using
both self-report and objective measures to capture outcome data. There is no cure on the horizon for FMS and there is
limited research on symptom management in persons with this disorder. The literature is especially limited when
examining this issue from the PNI perspective. Using the PNI model that includes both subjective and objective measures
to explore key variables, data from this study may be important in the development of nonpharmacological or other
interventions for management of sleep disturbance and other symptoms in women diagnosed with FMS.
K. COMPENSATION PLAN
Compensation for subjects (if applicable) should be described, including possible total compensation, any proposed
bonus, and any proposed reductions or penalties for not completing the project.
Upon completion of the study visit and assessment and determination of patient safety, a $25 gift card will be provided to
the participant as compensation for their time and effort.
L. CONSENT ISSUES
1. CONSENT PROCESS
Indicate who will be asked to provide consent/assent, who will obtain consent/assent, what language (e.g., English,
Spanish) will be used by those obtaining consent/assent, where and when will consent/assent be obtained, what steps
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will be taken to minimize the possibility of coercion or undue influence, and how much time will subjects be afforded
to make a decision to participate.
Informed consent will be obtained in a private setting. Potential participants can take as much time as needed to read or
discuss the consent with the study investigator, family or friends before making their decision. Furthermore, explanation of
the study will be provided verbally and in writing. Patients will be allowed to ask questions or call the study investigator to
discuss any concerns at any time.
2. SPECIAL CONSENT PROVISIONS
If some or all subjects will be cognitively impaired, or have language/hearing difficulties, describe how capacity for
consent will be determined. Please consider using the VCU Informed Consent Evaluation Instrument available at
http://www.research.vcu.edu/irb/guidance.htm. If you anticipate the need to obtain informed consent from legally
authorized representatives (LARs), please describe how you will identify an appropriate representative and ensure
that their consent is obtained. Guidance on LAR is available at http://www.research.vcu.edu/irb/wpp/flash/XI-3.htm.
N/A
3. If request is being made to WAIVE SOME OR ALL ELEMENTS OF INFORMED CONSENT FROM SUBJECTS OR
PERMISSION FROM PARENTS, explain why: (1) the research involves no more than minimal risk to the subjects, (2) the
waiver or alteration will not adversely affect the rights and welfare of the subjects, (3) the research could not
practicably be carried out without the waiver or alteration; AND (4) whether or not subjects will be debriefed after
their participation. Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/XI-1.htm.. NOTE: Waiver is
not allowed for FDA-regulated research unless it meets FDA requirements for Waiver of Consent for Emergency
Research (see below).
N/A
4. If request is being made to WAIVE DOCUMENTATION OF CONSENT, provide a justification for waiver based on one of
the following two elements AND include a description of the information that will be provided to participants: (1) the
only record linking the subject and the research would be the consent document and the principal risk would be
potential harm resulting from a breach of confidentiality. Subject will be asked whether they want documentation
linking them with the research, and each subject’s wishes will govern; or (2) the research presents no more than
minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside of
the research context. Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XI-2.htm
N/A
5. If applicable, explain the ASSENT PROCESS for children or decisionally impaired subjects. Describe the
procedures, if any, for re-consenting children upon attainment of adulthood. Describe procedures, if any, for
consenting subjects who are no longer decisionally impaired. Guidance is available at
http://www.research.vcu.edu/irb/wpp/flash/XV-2.htm and http://www.research.vcu.edu/irb/wpp/flash/XVII-7.htm.
N/A
6. If request is being made to WAIVE THE REQUIREMENT TO OBTAIN ASSENT from children age 7 or higher, or
decisionally impaired subjects, explain why: (1) why some or all of the individuals age 7 or higher will not be capable
of providing assent based on their developmental status or impact of illness; (2) the research holds out a prospect of
direct benefit not available outside of the research; AND/OR (3) [a] the research involves no more than minimal risk to
the subjects, [b] the waiver or alteration will not adversely affect the rights and welfare of the subjects, [c] the
research could not practicably be carried out without the waiver or alteration; AND [d] whether or not subjects will be
debriefed after their participation. Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/XV-2.htm
N/A
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7. If request is being made to waive consent for emergency research, see guidance at
http://www.research.vcu.edu/irb/wpp/flash/XVII-16.htm.
N/A
8. If applicable, address the following issues related to GENETIC TESTING:
a. FUTURE CONTACT CONCERNING FURTHER GENETIC TESTING RESEARCH
Describe the circumstances under which the subject might be contacted in the future concerning further participation
in this or related genetic testing research.
N/A
b. FUTURE CONTACT CONCERNING GENETIC TESTING RESULTS
If planned or possible future genetic testing results are unlikely to have clinical implications, then a statement that the
results will not be made available to subjects may be appropriate. If results might be of clinical significance, then
describe the circumstances and procedures by which subjects would receive results. Describe how subjects might
access genetic counseling for assistance in understanding the implications of genetic testing results, and whether this
might involve costs to subjects. Investigators should be aware that federal regulations, in general, require that testing
results used in clinical management must have been obtained in a CLIA-certified laboratory.
N/A
c. WITHDRAWAL OF GENETIC TESTING CONSENT
Describe whether and how subjects might, in the future, request to have test results and/or samples withdrawn in
order to prevent further analysis, reporting, and/or testing.
N/A
d. GENETIC TESTING INVOLVING CHILDREN OR DECISIONALLY IMPAIRED SUBJECTS
Describe procedures, if any, for consenting children upon the attainment of adulthood. Describe procedures, if any,
for consenting subjects who are no longer decisionally impaired.
N/A
e. CONFIDENTIALITY
Describe the extent to which genetic testing results will remain confidential and special precautions, if any, to protect
confidentiality.
N/A
APPENDICES
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The Brief Fatigue Inventory (BFI)
Perceived Stress Scale (PSS)
The Brief Pain Inventory (BPI)
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Biobehavioral Correlates in Fibromyalgia
Fibromyalgia (FMS) is a chronic pain syndrome characterized by diffuse musculoskeletal
pain, non-restorative sleep, fatigue, and psychological distress (Schaefer, 2003). The American
College of Rheumatology guidelines for diagnosis of FMS require widespread aching for at least
three months and the presence of 11 out of 18 possible tender points (Shah, Feinberg, &
Krishnan, 2006; Wolfe et al., 1990). It affects approximately five million Americans (Lawrence
et al., 2008), 90% of whom are women (Bennett, Jones, Turk, Russell, & Matallana, 2007). The
economic impact of this condition is substantial; individuals with FMS often have trouble
maintaining long-term employment due to increasing disability (Birtane, Uzunca, Tastekin, &
Tuna, 2007). Pain, disordered sleep, and fatigue have been ranked by people with FMS as
symptoms having great impact on quality of life (Theadom, Cropley, & Humphrey, 2007; Smith,
Harris, & Clauw, 2011).
The primary aim of this study was to compare two groups, 25 women with FMS and 25
without FMS, on the following variables: autonomic nervous system (ANS) activity; perceived
stress; sleep quality; immune function (17-plex cytokines); and fatigue. A secondary aim was to
explore the relationships among the above variables within each group of participants. A third
aim was to assess the construct validity of the Autonomic Symptoms Profile (ASP) in FMS
research by comparing it to measures of heart rate variability (HRV) and sleep indices (number
of arousals and sleep latency).
Psychoneuroimmunology (PNI) has been used as a framework to examine relationships
among biological and behavioral correlates and their effects on patient outcomes (McCain, Gray,
Walter, & Robins, 2005). Within that framework, this study posited that biological and
behavioral cofactors interact with the ANS in women with FMS to produce dysfunctional
changes in the ANS response to perceived stress, which in turn might alter sleep quality and
53

FIBROMYALGIA

cytokine expression. Poor sleep quality also leads to cytokine changes (Vgontzas et al., 1997);
both perceived stress and poor sleep quality interact with the ANS in a circular fashion, which
may result in generalized pain and fatigue. The conceptual framework for this research is
displayed in Figure 1.
Figure 1
PNI-based biobehavioral model of symptoms in FMS (adapted from McCain et al., 2005)

The extent to which expression of FMS symptoms is associated with cytokine changes
independently of poor sleep quality has been unclear. It is unknown which particular aspects of
sleep in FMS, such as length of sleep stages or number of arousals, may be predictive of
cytokine changes or resultant from them. Additionally, perceived stress has been implicated in
worsening sleep quality, pain, and fatigue for people with FMS, but the degree to which it
initiates or reflects ANS stress arousal remains uncertain.
Background
Disordered pain processing through central sensitization appears to play a role in the
development of FMS symptoms (Light et al., 2009). FMS is thought to result from ANS
dysfunction initiated by a genetically impaired stress response (Martinez-Lavin, 2007; Solano et
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al., 2009). ANS dysregulation of pain modulatory systems may lead to prolonged interactions
among the central nervous system, the peripheral nervous system, and the immune system, such
that neuroplasticity establishes a connection among the sympathetic nervous system (SNS) and
nocioceptive fibers. This is postulated to result in neuropathic pain (Light et al., 2009). In this
view the SNS is persistently hyperactive, yet paradoxically hypoactive to acute stressors due to
receptor desensitization. Thus the SNS is overwhelmed and due to a ceiling effect, unable to
respond appropriately to further stress (Martinez-Lavin, 2007).
Normal beat-to-beat HRV is the signature of a healthy ANS response to changes in the
environment, and HRV alteration may be a biomarker of stress (Staud, 2008). Consistent with
the premise that perceived stress increases SNS activity (Martinez-Lavin, 2007), participants
with FMS have displayed higher resting heart rates (Cohen et al., 2000) and decreased HRV as
compared to healthy controls (Dadabhoy, Crofford, Spaeth, Russell, & Clauw, 2008; Nilsen et
al., 2007; Lerma et al., 2011). Theadom and Cropley (2008) found that study participants with
FMS had significantly higher levels of perceived stress as compared to controls, which was
associated with intensified pain. Study participants with FMS also displayed greater stress
response to pain as compared with participants with osteoarthritis who reported similar pain
levels (Zautra et al., 2005). Perceived stress also has been independently associated with poor
sleep quality and increased nighttime arousals in persons with FMS (Theadom & Cropley, 2008).
Nearly 100% of individuals with FMS report poor sleep quality (Rizzi et al., 2004). They
have endorsed sleeping an average of four to six hours per night and arising unrefreshed (Osorio,
Gallinaro, Lorenzi-Filho, & Lage, 2006). Sleep disturbances commonly reported have included
difficulty falling asleep, nighttime arousals, and fatigue upon arising (Bigatti, Hernandez,
Cronan, & Rand, 2008). These findings have been supported by polysomnography (PSG) and

55

FIBROMYALGIA

actigraphy, which suggest that study participants with FMS are more easily aroused from sleep
(Rizzi et al., 2004; Landis et al., 2003) and have higher levels of physical activity at night than
controls (Shah et al., 2006). People with FMS have been shown to experience protracted sleep
latency, reduced sleep efficiency, reduced slow wave and REM sleep, increased motor activity
during sleep, and increased alpha EEG activity during non-REM sleep (Moldofsky &
MacFarlane, 2005). Study participants with FMS have displayed significantly shorter duration
of non-REM stage 2 (N2) sleep than controls, which was predictive of pain (Landis et al., 2003).
Other PSG findings in patients with FMS have included decreased total sleep time and decreased
delta sleep (Harding & Hawkins, 2005). Restless leg syndrome (RLS) and periodic limb
movement disorder (PLMD) are reported to occur in 20% of people with FMS as opposed to 5 to
10% in the general population (Moldofsky & MacFarlane, 2005).
Poor sleep also has been associated with greater pain (Bigatti et al., 2008) and fatigue
(Hamilton et al., 2008) in persons with FMS. Conversely, improved sleep quality has been
associated with decreased pain and fatigue and is viewed as a barometer for clinical symptom
management among those with FMS (Perrot, Dickenson, & Bennett, 2008; Peterson, 2007). No
systematic studies have shown that treating RLS, PLMD, or obstructive sleep apnea (OSA)
improves the poor sleep, fatigue, and pain typically experienced by those with FMS (Moldofsky
& MacFarlane, 2005). The extent to which various sleep disorders may be considered a part of
the underlying ANS dysfunction posited for FMS remains unknown.
Cytokines are polypeptides that act as messengers between immune cells (among others);
they are critical to cell growth, repair, and modulation of pro- and anti-inflammatory immune
responses (Wallace, 2006). Interactions among the hypothalamic-pituitary-adrenal (HPA) axis,
the SNS, and cytokines help regulate sleep, stress responses, pain perception, and fatigue
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(Wallace, 2006). The pro-inflammatory cytokines interleukin 1-beta (IL-1β) and tumor necrosis
factor-alpha (TNF-α) have been related to symptoms associated with sleep deprivation, such as
pain and fatigue (Krueger, 2008; Opp, 2006). IL-1 and TNF-α have been shown to enhance EEG
slow waves, increase the duration of NREM sleep, and reduce REM sleep (Imeri & Opp, 2009).
Alterations in various cytokine levels have been reported in study participants with FMS,
but this is a developing field, with varying study methods and contradictory results (Menzies &
Lyon, 2010). It has been suggested that there may be an imbalance in persons with FMS in favor
of sleep-disturbing anti-inflammatory cytokine responses during sleep (Togo et al., 2009). Yet in
40 study participants with widespread pain, 26 of whom had FMS (vs. controls), no significant
increase in pro-inflammatory cytokines, and no significant correlations among cytokine levels
and fatigue in those with FMS were found (Uceyler et al., 2006). From an integrative review of
cytokines in FMS, Menzies and Lyon (2010) concluded that there are discrepancies regarding
whether pro- or anti-inflammatory cytokines are elevated or reduced in FMS, and whether they
correlate with FMS symptoms. The same group later reported that fatigue in participants with
FMS was found to negatively correlate with IL-1β, IL-10, and granulocyte colony-stimulating
factor (G-CSF) (Menzies, Lyon, Elswick, Jr., Montpetit, & McCain, 2011). However, in a recent
meta-analysis of cytokine research in FMS, other authors concluded that the majority of
investigated cytokines were not found to differ significantly between study participants with
FMS and controls (Uceyler, Hauser, & Sommer, 2011). Given this current degree of uncertainty,
more research has been called for to clarify what role cytokine levels may play in the etiology of
or immunological response to FMS. This study adds to the growing body of evidence
concerning cytokine alterations in relation to FMS.
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Research Design and Methods
A university sleep center was the setting for this study. Using a single stage crosssectional design, a total of 50 women, 25 with a recorded diagnosis of FMS, and 25 without that
diagnosis, were recruited. All the women had been referred to the sleep center for evaluation of
their sleep complaints. The sample was designed to include English-speaking women aged 35 to
65, without rheumatologic comorbidities, and not pregnant. Participants without a diagnosis of
FMS were queried for the presence of chronic widespread pain to avoid including persons with
undiagnosed FMS in the comparison group. Study measures are outlined in Table 1.
Table 1
Study Measures
Variable

Measure

Type

FMS

Demographic data

Questionnaire

ANS activity

Autonomic Symptom Profile (ASP)

73- item scale

Heart rate variability (HRV)

Sleep study ECG

Immune Function

Plasma 17-plex cytokines

8 ml blood sample

Stress

Perceived Stress Scale (PSS)

10-item scale

Sleep Quality

Pittsburgh Sleep Quality Index (PSQI)

19-item scale

Polysomnography (PSG)

Sleep study

Brief Fatigue Inventory (BFI)

10-item scale

Fatigue

ANS function was measured with the Autonomic Symptom Scale (ASP), a
multidimensional questionnaire that assesses orthostatic, secretomotor, sexual, urinary,
gastrointestinal, pupillomotor, vasomotor, reflex syncope, and sleep symptoms. The highest
possible score for women is 170. Higher ASP scores have been significantly positively
correlated with the Fibromyalgia Impact Questionnaire (FIQ) (Solano et al., 2009). Lerma et al.
(2011) reported mean ASP scores of 53.6 ± 18.2 for participants with FMS as compared to 13.5
± 10.6 for healthy controls (p < 0. 0001).
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HRV time-domain measures were used to explore ANS function; these were obtained
from the ECG recording that is part of the PSG in the sleep center. Time domain HRV measures
are based on the mean interval between normal sinus beats on ECG, referred to as RR intervals
(also known as NN intervals). These are computer analyzed to acquire additional variables such
SDNN (standard deviation of NN intervals); SDANN (mean standard deviation of average NN
intervals calculated over 5 minutes); pNN50 (percentage of pairs of successive NN intervals
differing by >50 milliseconds); and SDNN index (the mean of all the 5-minute standard
deviations of NN). SDNN and SDANN are indicative of overall HRV; pNN50 evaluates the
number of large beat to beat fluctuations (Bilchick & Berger, 2006).
Perceived stress was measured with the 10-item Perceived Stress Scale (PSS), which
indicates self-reported frequency of stressful events over a month’s time, perceived control, the
degree to which situations are perceived to be stressful, and ability to cope (Cohen &
Williamson, 1988). It has a reliability coefficient for the 10-item version of α = 0.91 (Mitchell,
Crane, & Kim, 2008).
The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality and
disturbances over a one month interval. Its components yield a global score from 0 to 21. The
PSQI global score correlation coefficient for test-retest reliability was reported to be 0.87; a
global score >5 resulted in a sensitivity of 98.7 and specificity of 84.4 as a marker for sleep
disturbance in patients with insomnia versus controls (Backhaus, Junghanns, Broocks, Riemann,
& Hohagen, 2002).
Sleep duration and quality were also measured with polysomnography (PSG), an array of
physiologic measures to study sleep duration and quality, including central and occipital EEG,
eye movement monitoring, muscle tension in several locations, ECG, airflow, respiratory rate,
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oxygen saturation, limb movements, and expired CO2. The PSG was performed in an outpatient
sleep laboratory overnight with sleep technologists. The entire battery of tests is arrayed on a
computer monitor and sleep stages (wake, N1, N2, N3, and REM) are visually scored for 30second epochs according to the criteria of Rechtschaffen and Kales (Berry, Geyer, & Carney,
2005). The PSG is the primary means of diagnosing obstructive sleep apnea (OSA). Apnea is
defined as the cessation of airflow for at least 10 seconds; a decrease but not total cessation of
airflow that lasts 10 seconds is considered hypopnea. Apnea-hypopnea index (AHI) is the
average number of hourly apnea and hypopnea episodes found on PSG; an AHI greater than five
events per hour is indicative of obstructive sleep apnea (OSA). Mild OSA is characterized by an
AHI between 5 to 15 events per hour. Moderate OSA is diagnosed when AHI values range from
15 to 30. Severe OSA occurs when the AHI is above 30 (Guilleminault & Bassiri, 2005).
Fatigue was measured using the Brief Fatigue Inventory (BFI), which assesses fatigue
severity and interference in daily life. It uses numeric rating scales from 0 to 10. Severe fatigue
is a score of 7 or higher (Mendoza et al., 1999). The BFI has demonstrated reliability in clinical
trials, ranging from 0.82 to 0.97 (MD Anderson website, 2010).
Cytokine samples were collected via peripheral venous blood samples obtained by sterile
venipuncture using cell preparation tubes with sodium heparin. Plasma samples were analyzed
using the Bio-Plex Plus® Human 17-Plex (Bio-Rad: Hercules, CA) multiplex magnetic bead
assay system. The standardized 17-Plex kit includes coupled beads, detection antibodies, and
standards for the detection of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL17, granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating
factor (GM-CSF), interferon-gamma (IFN-γ), monocyte chemoattractant protein-1 (MCP-1),
macrophage inflammatory protein-1β (MIP-1β), and TNF-α.
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Potential participants were recruited from the VCU Center for Sleep Medicine schedule
of patients following initial screening for inclusion/exclusion criteria. Women who met the
study criteria were given a verbal and a written explanation of the study. Those who agreed to
participate met the investigator at the sleep center 90 minutes prior to the scheduled clinical sleep
study. The participants consented in writing after a verbal review of the study, completed the
study psychosocial measures, and then had a blood sample collected. After data collection,
participants were compensated for their time with a $25 gift card. Technologists conducted the
PSG; a neurologist board certified in sleep medicine interpreted the PSG findings. If patients
required titration of continuous positive airway pressure (CPAP) for sleep apnea, it was initiated
per protocol. The blood sample was transported in a cold-pack biohazard container to the
laboratory. All blood samples were centrifuged for plasma separation; specimens were
aliquoted, frozen, and stored at -70° C until all samples had been collected and they were batch
processed using standard procedures performed by a highly experienced technician.
Descriptive statistics of the demographic variables for the two groups were compared
with means and SEs for continuous data and frequency distributions and percentages for
categorical data. For the demographic variables, differences between the groups were assessed
using two-sample t-tests for continuous data and Chi-square for categorical data. In Aim 1, it
was hypothesized that the FMS group as compared to the non-FMS group would demonstrate
significantly more autonomic symptoms, stress, fatigue, and sleep disturbance; lower HRV and
sleep quality; and an altered ratio of pro- to anti-inflammatory cytokines. For Aim 2, Pearson’s
correlations among ANS activity, perceived stress, sleep quality, immune function (cytokines),
and fatigue were explored within each group. It was hypothesized that different correlation
patterns would be observed in the FMS group than the non-FMS group. To study Aim 3,
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construct validity of the ASP was explored by examining Pearson’s correlations between ASP
scores and HRV, arousals, and stages of sleep. Statistical analyses were performed using JMP
9.0, and significance set at α ≤ 0.05.
The two groups were compared on the basis of AHI. These data were not normally
distributed and thus were log transformed. The groups differed significantly on the basis of log
AHI, with 20% of the FMS group having OSA (mean = 0.95, SE = 2.53), while 80% of the nonFMS group had OSA (mean = 2.33, SE = 0.28, p = 0.0008). Hence, AHI was factored into
ANCOVA testing by using log AHI, group, and group by AHI as model effects initially, then
using only group and log AHI if the interaction between those two variables was not significant.
Log AHI also was used as a covariate in the models used to test for significant group differences
in ANS activity, perceived stress, sleep quality, immune function, and fatigue.
Findings
A demographic questionnaire was used to obtain information regarding age, height,
weight, race/ethnicity, partner status, education, medical history, and socioeconomic status. As
shown in Table 2, the two study groups did not differ significantly on the basis of age, weight,
BMI, menstrual status, marital status, or income. The prevalence of hypertension and diabetes
mellitus was not significantly different between the groups. There was a significant difference
between the groups in their racial proportions. The non-FMS group was significantly more
likely to have African American members. The FMS group women were significantly more
likely to be disabled, and the non-FMS group was more likely to be employed.
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Table 2
Demographic Data
Demographic
characteristic
Age
(Range 35-65)
Weight
BMI

Total
N = 50

Non-FMS group

FMS group

Statistics

52 (CI = 49-54)

52 (CI = 48-55)

52.5(CI = 49-56)

p = 0.7

200 (CI = 187-214)

208 (CI = 188-228)

193 (CI = 174-213)

p = 0.27

34 (CI = 32-36)

35.9(CI = 33-39)

32 (CI = 29-35)

p= 0.09

20

5

15

30

20

10

Pearson’s
p = 0.0039*

9
41

7
18

2
23

Fisher’s
p = 0.138

17
17
12
4

6
9
6
4

11
8
6
0

8
18
24

6
8
11

2
10
13

Pearson’s
p = 0.30

38
12
19

12
8
5

7
4
14

Pearson’s
p = 0.0316*

22

11

11

14
7
7

7
4
3

7
3
4

Pearson’s
p = 0.96

32

16

16

Pearson’s
p = 1.0

11

6

5

Pearson’s
p = 0.73

Race/ethnicity
Caucasian
African American
Menstrual status
Premenopausal
Postmenopausal
Marital status
Divorced
Partnered
Single
Widowed

Pearson’s
p = 0.1369

Education
8th grade
High school
College
Work status
Employed
Unemployed
Disabled
Income
Below 15,000
15,000-44,999
45,000-89,999
Above 90,000
Hypertension
Diabetes
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Study Aim 1
The FMS group had significantly higher ASP scores than the non-FMS group. The mean
ASP score was nearly twice as high for the FMS group (mean = 42, SE = 3.48, CI = 34.99-49)
than the non-FMS group (mean = 23.8, SE = 3.48, CI = 16.79-30.81) (p = 0.029). No
significant difference between the two groups was found on the basis of total PSS (p = 0.26).
Both groups had elevated stress as compared to established norms. PSS mean score norms are
12.8 (SD = 6.2) for whites and 14.7 (SD = 7.2) for African Americans; for women in general the
mean score is 13.7 (SD = 6.6) (Cohen, 1994). In the current study, the mean PSS for the FMS
group was 21.9 (SD = 8.0, CI = 18.6-25.2); it was 19.1 (SD = 6.3, CI = 16.5-21.7) for the nonFMS group.
Both groups reported poor sleep quality but the FMS group had significantly higher PSQI
scores (mean = 15.08, SE = 0.68, CI = 13.7-16.45) than the non-FMS group (mean = 11.24, SE
= 0.68, CI = 9.86-12.61) (p = 0.0011). The FMS group also had significantly higher BFI scores
(mean = 66.24, SE = 3.75, CI = 58.69-73.78) than the non-FMS group (mean = 44.92, SE = 3.75,
CI = 37.37-52.46) (p = 0.0006). However, the groups did not differ significantly on the basis of
sleep stages derived from PSG data, as reported in Table 3.
Table 3
Sleep by group
FMS group

Non-FMS group

Mean

SE

CI

Mean

SE

CI

p-value

Total Wake Time

50.1

9.9

29.6-70.6

61.4

8.4

44-78.8

0.39

Total Sleep Time

627.7

240.9

130.4-1125

387.3

17.9

350.3-424.3

0.20

Non-REM: N1

20.8

2.4

15.9-25.7

25.4

2.6

19.9-3.9

0.40

N2

192.3

13.6

164.3-220.3

208.5

10.1

187.5-229.5

0.58

N3

106.4

12.5

80.6-132

314.6

240.4

-181.6-810.8

0.52

68.2

7

53.7-82.7

74

6.7

60.2-87.9

0.35

REM
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Arousals were scored according to the rules of the American Academy of Sleep Medicine
(1992). As indicated in Table 4, arousals were not found to be significantly different on the basis
of group status. Mean hourly arousal norms for healthy individuals aged 41 to 60 range from
14.9 to 16.2 (Bonnet & Arand, 2007). In this sample total arousals (p = 0.002) and respiratory
arousals (p = 0.0001) were found to be elevated when increased Log AHI was high, however.
Table 4
Arousals by group
FMS group

Non-FMS group

Mean

SE

CI

Mean

SE

CI

p-value

Total arousals

93

11.83

69-116

129

11.83

106-153

0.39

Spontaneous arousals

45

4.94

35-55

43

4.94

33-53

0.81

Limb-movement
arousals

17

5.69

6-29

19

5.69

8-31

0.45

Respiratory arousals

31

9.84

11-51

67

9.84

47-87

0.57

Hourly arousals

15

2.14

11-19

20

2.14

16-25

0.42

Cytokine data were log transformed as they were not normally distributed. Of the 17
cytokine levels assayed, only IL-1β and TNF-α varied significantly between the groups. The IL1β levels per group were not significantly different when log AHI was less than 1.6 (p = 0.195),
but at 1.6 (equivalent to AHI of 5, the cut-off point for diagnosis of OSA), the non-FMS group
had significantly higher IL-1β levels than the FMS group (p = 0.0486). When log AHI was
greater than 1.6, the difference was even more pronounced (p = 0.00096). For TNF-α, the FMS
group had significantly higher log TNF-α values (mean = 0.907, SE = 0.5047, CI = -0.11-1.925)
than the non-FMS group (mean = -0.436, SE = 0.4721, CI = -1.389-0.516) (p = 0.0116).
The FMS group demonstrated significantly lower SDNN as compared to the non-FMS
group, as indicated in Table 5. However, SDNN had a significant group by Log AHI interaction
such that SDNN declined as Log AHI increased in the non-FMS group.
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Table 5
HRV by group
FMS group

Non-FMS group

Mean

SE

CI

Mean

SE

CI

p-value

RR interval

885.7

27.8

828.4-943

868.8

30.8

805.1-932.4

0.42

SDNN

97.4

14.3

67.8-126.9

148.6

46.3

53-244

0.014*

SDANN

136.3

24.9

84.8-187.7

78.5

12.7

52.3-104.8

0.133

pNN50

12.8

3.6

5.3-20.3

16.9

2.8

11-22.7

0.088

SDNN index

46.4

5.5

34.9-57.8

51

6

38.5-63.6

0.81

Study Aim 2
Pearson’s correlation coefficients were calculated to determine if there were significant
relationships among ANS activity, perceived stress, sleep quality, immune function (cytokines),
and fatigue within each group. As displayed in Table 6 for the FMS group, the BFI was
positively correlated with the PSS, the ASP, and TNF-α; the PSS was also positively correlated
with the ASP. AHI was correlated with total arousals and was negatively correlated with IL-1β.
Table 6
FMS Group Correlations
BFI

PSS

AHI Arousal

PSS

0.4495*

AHI

-0.1653

-0.0975

Arousal -0.2283

-0.3420

0.4008*

RR

SDNN

PSQI

IL-1β TNF-α

RR

0.0645

-0.0395

-0.1595

-0.2478

SDNN

0..1390

0.2570

0.1007

-0.1417

0.0762

PSQI

0.0083

0.2052

-0.3041

-0.0537

0.0904

IL-1β

-0.0672

0.0814

-0.4445* -0.3347

-0.3297 -0.0093 0.4089

TNF-α

0.4512* 0.2837

0.1809

0.3287

0.0079

0.3631

ASP

0.4122* 0.6628** -0.2487

-0.3590

0.0286

-0.0647 0.1687 0.2926

*p ≤ 0.05. **p ≤ 0.001.
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In the non-FMS group (Table 7), the PSQI was positively correlated with the BFI and
both were positively correlated with IL-1β. IL-1β was positively correlated with TNF-α. Total
arousals were correlated with AHI and negatively correlated with mean RR interval. SDNN was
correlated with RR interval and negatively correlated with AHI.
Table 7
Non-FMS Group Correlations
BFI

PSS

AHI Arousals

PSS

0.3505

AHI

0.1583

0.0175

Arousals 0.3666

0.0359

0.4511*

RR

SDNN

PSQI

IL-1β

RR

-0.0904

0.1638

-0.5876* -0.4175*

SDNN

-0.1033

0.2345

-0.6551** -0.2605

0.7346**

PSQI

0.4315*

0.2048

0.1277

-0.0889

0.0819

-0.0774

IL-1β

0.4980*

0.2195

0.2723

0.2186

0.0585

-0.1241

0.4274*

TNF-α

0.2897

0.0417

0.3610

0.1903

-0.0927

-0.1907

0.2995

0.8462**

ASP

0.3587

0.1145

0.1095

0.0698

0.0932

-0.1495

0.2526

0.3135

TNF-a

-0.0274

*p ≤ 0.05. **p ≤ 0.001.
Table 8 displays the significant correlations contrasted for the two groups. Only the
positive correlation of total arousals with AHI was shared by both groups. All other FMS group
variables that were significantly correlated were different than the significant correlations found
in the non-FMS group.
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Table 8
Significant correlations by group
Correlations

FMS

Non-FMS

PSS by BFI

0.4495*

0.3505

Arousals by AHI

0.4008*

0.4511*

RR by AHI

-0.1595

-0.5876*

RR by arousals

-0.2478

-0.4175*

SDNN by AHI

0.1007

-0.6551**

SDNN by RR

0.0762

0.7346**

PSQI by BFI

0.0083

0.4315*

IL-1β by BFI

-0.0672

0.4980*

IL-1β by AHI

-0.4445*

0.2723

IL-1β by PSQI

0.4089

0.4274*

TNF-α by BFI

0.4512*

0.2897

TNF-α by IL-1β

-0.1525

0.8462**

ASP by BFI

0.4122*

0.3587

ASP by PSS

0.6628**

0.1145

*p ≤ 0.05; **p ≤ 0.001.
Study Aim 3
Pearson’s correlation coefficients were calculated to determine the relationships among
ASP scores, HRV, and sleep stages for each group. As noted above, the ASP did not have any
significant correlations with Log AHI, total arousals, SDNN, or RR interval in either group. No
significant correlation of the ASP with any HRV measure, arousal, or stage of sleep was
detected, as indicated in Table 9.
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Table 9
ASP correlations by group
Variable

FMS

Non-FMS

SDANN

-.1448

0.0381

SDNN index

-0.1214

0.1584

pNN50

0.0920

0.1684

Spontaneous arousals

-0.2674

-0.0912

Hourly arousals

-0.3774

-0.1147

Non-REM: N1 sleep

-0.1649

0.2867

N2 sleep

-0.1004

0.1738

N3 sleep

0.2014

-0.0405

0.2178

0.2869

REM sleep

In summary, findings of this study indicated that the FMS group had significantly worse
sleep quality, more autonomic symptoms, and greater fatigue than the non-FMS group; they also
had higher TNF-α levels. The non-FMS group was significantly more likely to have OSA. NonFMS participants who had OSA also had significantly higher IL-1β values than the FMS group.
Study variables that significantly correlated with each other in the FMS group differed from
those seen in the non-FMS group, with the exception of the positive correlation of total arousals
with AHI in both groups. In the FMS group, fatigue was positively correlated with perceived
stress, autonomic symptoms, and TNF-α; stress was positively correlated with autonomic
symptoms; and AHI was negatively correlated with IL-1β levels as well as the above noted
correlation with total arousals. In the non-FMS group, sleep quality was positively correlated
with fatigue, and sleep quality and fatigue were positively correlated with IL-1β. IL-1β also
positively correlated with TNF-α. Total arousals were significantly correlated with AHI and
significantly negatively correlated with mean RR interval. SDNN was significantly correlated
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with RR interval and significantly negatively correlated with AHI. The hypothesis tests related
to construct validity of the ASP indicated no significant supportive correlations.
Discussion
Menzies et al. (2011) found that perceived stress significantly positively correlated with
fatigue in their study of 50 participants with FMS. The results from this study are in accord with
that finding. The additional strong positive correlation of fatigue and stress with autonomic
symptoms in the FMS group adds additional support for the PNI framework characterized by
those authors. Specifically, the type and degree of autonomic symptoms present in persons with
FMS may be markers that reflect increases in perceived stress and fatigue, but the direction of
any possible effect remains unknown.
In this study there was a significantly higher level of TNF-α in the FMS group as
compared to the non-FMS group. This finding was unexpected because a previous meta-analysis
found no significant differences in TNF-α levels between study participants with FMS and
controls (Uceyler et al., 2011). Plasma levels of TNF-α have been consistently found to be
elevated in the presence of OSA (Alberti et al., 2003; Sahlman et al., 2010; Vgontzas et al.,
1997) and positively correlated with AHI in one study (Ciftci, Kokturk, Bukan, & Bilgihan,
2004). The positive interaction between TNF-α and Log AHI complicates this picture and
cannot be accurately interpreted because this study lacked a normal control group.
There was a positive correlation with TNF-α and fatigue in the FMS group. This is also a
unique finding; no significant correlations between FMS-related fatigue and TNF-α were found
in at least two other studies (Menzies et al., 2011; Uceyler et al., 2006). No association between
TNF-α and fatigue was found in the non-FMS group, which had lower TNF-α levels and less
fatigue than the FMS group. It is therefore plausible that the increased TNF-α in the FMS group
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may be directly related to their greater experience of fatigue, independent of sleep quality as
suggested by the lack of correlation in this group between sleep quality and fatigue.
It is unclear why the non-FMS group in the setting of higher AHI displayed significantly
higher IL-1β values than the FMS group. No significant differences in plasma IL-1β between
people with OSA and healthy controls have been found by some investigators (Alberti et al.,
2003; Vgontzas et al., 1997). However, one study reported significantly lower serum
concentrations of IL-1β among people with mild OSA (AHI between 5 and 15) as compared to
control participants, and in the participants with OSA, lower IL-1β was associated with higher
AHI (Sahlman et al., 2010). No differences in levels of IL-1β have been previously reported in
persons with FMS as compared to controls (Uceyler et al., 2006). In the current study IL-1β
significantly positively covaried with TNF-α, sleep quality, and fatigue in the non-FMS group
even though fatigue and TNF-α were not significantly correlated with each other. IL-1β was
found to significantly negatively correlate with AHI in the FMS group, which is contrary to the
findings in the non-FMS group, even though the non-FMS demonstrated higher AHI.
Four of the five HRV comparisons between the two groups did not display a significant
difference in this study, in contrast to consistent findings of decreased HRV in study participants
with FMS as compared to healthy controls in previous studies (Dadabhoy et al., 2008; Nilsen et
al., 2007; Lerma et al., 2011; Chervin et al., 2009). However, SDNN, a marker of overall HRV,
was significantly lower in the FMS group; this was found despite confounding of increased AHI
in the non-FMS group in association with lower SDNN. Non-significant HRV findings for the
FMS group also may be related to the high incidence of OSA in the non-FMS group. In healthy
subjects nighttime EEG arousals are preceded by an increase in heart rate (HR). This effectively
lowers the HRV as HR increases (Versace, Mozzato, De Min, Cavallero, & Stegagno, 2003).
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One might expect that increased numbers of arousals of any kind would therefore raise overall
HR and decrease HRV. Patients with OSA have displayed decreased time- and frequencydomain HRV measures as compared to healthy individuals during wake time (Balachandran et
al., 2012). The literature on this topic is inconsistent, however, with some studies indicating
greater nighttime HRV in OSA, and others reporting no significant differences (Sforza, Pichot,
Cervena, Barthelemy, & Roche, 2007).
Mean RR intervals did not negatively covary with arousals in FMS participants, as they
did in the non-FMS group; this may support the notion of a defect in ANS activity in FMS. Both
groups did display a similar arousal response to apnea episodes, as indicated by the significant
association of total arousals with AHI. Interestingly, in the non-FMS group fatigue was
correlated with poor sleep quality, but this was not found in the FMS group. In the FMS group, a
heightened presence of autonomic symptoms (i.e., faintness, palpitations, GI instability, and
blurred vision) was correlated with fatigue and highly associated with perceived stress.
Perceived stress has been implicated in worsening sleep quality and fatigue for people with FMS,
but the degree to which it initiates or reflects ANS stress arousal remains unclear; there was not a
significant group difference in perceived stress detected in this study. It is still unknown which
particular aspects of sleep in FMS, such as length of sleep stages or number of arousals, may be
predictive of cytokine changes or resultant from them. Objective sleep measures did not capture
any significant differences that might account for the poorer sleep quality reported by
participants with FMS. This is consistent with the findings of Chervin et al. (2009), who found
no objective markers of sleep disturbance specific for FMS.
These findings suggest a need to refine the postulated biobehavioral model of FMS as a
response to a dysfunction of the ANS. Specifically, it may be that genetic predisposition,
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psychosocial experience, and behavioral cofactors interact in women with FMS to produce ANS
changes that alter response to perceived stress and increase SNS predominance during sleep.
There is evidence that poor sleep quality may precede the onset of other FMS symptoms
although this is highly controversial (Gupta et al., 2007; Mork & Nilsen, 2012). The SNS is
viewed as persistently hyperactive, yet paradoxically hypoactive to stressors such as nighttime
arousals, which may affect cytokine expression. Autonomic symptoms, including poor sleep
quality, and perceived stress may lead to additional cytokine changes, all of which interact with
the ANS in a circular fashion, resulting in generalized fatigue.
Conclusion
The implications for nursing research are that this study may shed light on the complex
relationships of these variables in FMS in anticipation of formulating targeted nursing
interventions for sleep symptom management. There is no regimen that alleviates FMS sleep
symptoms consistently. Medications such as minalcipran, duloxetine, amitriptaline, and
pregabalin have provided limited pain relief for some patients with FMS, which helps promote
better sleep but is often not tolerated due to side effects (Hauser, Wolfe, Tolle, Uceyler, &
Sommer, 2012). Sodium oxybate, a sleep agent approved for use in narcolepsy, was not
approved by the FDA in 2011 for treatment of poor sleep quality in FMS, despite its reported
efficacy in clinical trials.
Complementary and alternative therapies such as guided imagery are modalities that have
been explored for FMS treatment in pilot studies and have shown promise for sleep symptom
management (Menzies, Taylor, & Bourguignon, 2006). It is anticipated that such research
efforts will continue. Future directions for research include randomized controlled trials of the
effects of alternative modalities such as guided imagery or Reiki on autonomic symptoms as
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measured by the ASP, frequency-domain as well as time-domain HRV measures, and sleep
quality in women with FMS.
Limitations
As a correlational study, inferences regarding causality cannot be made. A crosssectional design does not capture changes that occur as a result of environment or other events
that occur over time. The FMS group was not compared to healthy controls, but to individuals
who had reported poor sleep quality, thus the differences between the two groups in this study
are likely related to the high incidence of OSA in the non-FMS group (80%) as opposed to the
FMS group (20%). The small subset of women who had both FMS and OSA may have unique
characteristics not common to either group, but a detailed analysis of such a small number (n =
5) was not possible. This confounding factor must be addressed in future studies by the addition
of a healthy control group. The use of any medications or continuous positive airway pressure
(CPAP) therapy was not controlled because this was an observational study. Only one blood
draw for cytokines was performed, and this was prior to the PSG; a second blood draw in the
morning may have revealed more information. Finally, use of frequency-domain HRV measures
in addition to time-domain measures in future studies might be more revealing as these have
been reported to be more sensitive in differentiating persons with sleep fragmentation related to
respiratory events (Sforza et al., 2007).
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